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While alternative splicing is involved in the regulations of normal physiological 
functions and pathologies in human genome, an efficient tool for genome-wide 
splicing analysis is extremely needed to explore the detailed splicing changes 
and possible mechanisms of the splicing changes. However, existing software 
tools can only distinguish alternative splicing events with simple splicing 
patterns, and the remaining more than 30% complex splicing events are left 
unexplored. To tackle with this problem, a new genome-wide computational 
pipeline named SpliceScan was developed in this thesis to identify all 
differential splicing events based on the RNA-Seq data.  
We compared the SpliceScan performance with the widely used splicing 
software tools based on the MDS experimental data, and found that SpliceScan 
stands out for its more precise prediction and minimal computational running 
time, indicating that SpliceScan is a superior software tool in computational 
splicing analysis. 
We deployed SpliceScan to identify differential splicing events in 
myelodyspastic syndrome (MDS) patients with ZRSR2 mutation and in ZRSR2 
knockdown TF-1 leukemia cell lines compared to the MDS patients with 
ZRSR2 wildtype and normal bone marrow (BM), which are used as controls in 
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the comparison. Both the clinical samples and cell line samples showed an 
increase of differential splicing events when compared to the controls. Among 
all the splicing events, intron retention was the most affected splicing pattern in 
this study. We identified more than 90% of these differential splicing events are 
related to U12-type introns. However, U12-type intron is a minor intron, which 
only takes over 0.3% in human genome. These findings demonstrated that 
ZRSR2 regulated alternative splicing in hematological diseases and played an 
indispensable role in splicing of U12-type intron. 
SpliceScan also successfully predicted the differential splicing events in MCF7 
breast cancer samples under normoxia, acute hypoxia and chronic hypoxia 
conditions. Both the acute and chronic hypoxia conditions lead to an increase in 
the number of differential splicing candidates compared to the normoxia 
condition. Experimental validation confirms that some differential splicing 
events are universal in other hypoxia cell lines. An exonic splicing enhancer 
with a motif region “GGWC” is discovered during the exon skipping analysis 
in hypoxia. Exons bound with less “GGWC” motif have higher possibility to be 
exclusive under chronic hypoxia treatment. Our results showed these 
differentially spliced genes played an important role in response to hypoxia. 
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Chapter 1. Introduction 
1.1.  Splicing 
In molecular biology, splicing is an important step where certain intervening 
sequences from the precursor messenger RNA (pre-mRNA) are removed, and 
the remaining sequences are ligated to form the final mRNA for protein 
synthesis. Throughout this thesis, the “spliced out” intervening sequences will 
be called introns and the remaining sequences that joined together to form the 
final mRNA will be called exons. Not only observed in eukaryotic genes, 
introns are also observed in ribosomal RNA (rRNA), transfer RNA (tRNA), and 
many viruses.  
Depended on the structure of the spliced intron and the required catalysts, there 
are several types of RNA splicing exist, namely spliceosomal RNA splicing, 
self splicing and tRNA splicing. Based on the type of spliceosome assembly, 
spliceosomal RNA splicing can be further categorized into the major 
spliceosome pathway and the minor spliceosome pathway. On the other hand, 
RNA splicing could also be classified into intramolecular cis splicing and 
intermolecular trans splicing.  
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1.1.1 Alternative splicing 
In human cells, about 95% of the multi exonic genes exhibit alternative splicing. 
As the name suggests, alternative splicing is first known to be a process where 
exons from the pre-mRNA are alternatively included into or excluded from the 
mature mRNA. As studies and research goes on, the definition of alternative 
splicing expands and is no longer limited to exon skipping or mutually exclusive 
exons patterns, new alternative splicing patterns like intron retention, alternative 
5’ donor sites and alternative 3’ acceptor sites are included. In this way, 
alternative splicing enables a single gene to encode for multiple mature mRNA, 
and results in differences in the amino acid sequence of the proteins translated 
from the mRNA. As a result, many more proteins are synthesized in the human 
genome from its 20,000 protein coding genes than expected. Aside from 
increasing the biodiversity of proteins coded by genes, alternative splicing is 
also known to be the cause of certain genetic diseases when abnormal variations 
in splicing happens.  
1.1.2 The discovery of alternative splicing 
In the 1980s, alternative splicing was thought to be the peculiar characteristics 
of a limited number of genes (Early et al., 1980; Leff et al., 1986; Maki et al., 
1981; Rosenfeld et al., 1981; Rosenfeld et al., 1982). Even in 1990s, it was 
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believed that alternative splicing was restricted to a small subgroup of genes, 
holding less than 5% in human genome (Sharp, 1994). With the development 
of next-generation sequencing technology, an increasing number of alternative 
splicing events were identified in human cells as well as in other species. 
However, it was not until the beginning of this century that alternative splicing 
was ubiquitously proven in eukaryotes (Modrek and Lee, 2002).  
Nevertheless, the percentage of alternative splicing hugely varies across 
different species. Among all the eukaryotic species, the percentage of 
alternative splicing in vertebrate species is much higher than that in 
invertebrates (Keren et al., 2010). Approximately 95% of multi-exonic genes 
produce different mRNA transcripts in the human genome while only 60% of 
Drosophila genes have multiple transcripts (Graveley et al., 2011; Pan et al., 
2008). However, the percentage of alternative splicing in plants is even lower, 
and only about 20% genes encode different transcripts (Barbazuk et al., 2008). 
In some way, alternative splicing across different species follows the 
evolutionary path of the last 350 million years (Barbosa-Morais et al., 2012; 
Gelfman et al., 2012; Irimia et al., 2009; Nilsen and Graveley, 2010). In general, 
alternative splicing contributes to promote the diversification of RNA 
transcriptome and various functional proteome. 
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1.1.3 Alternative splicing pattern classification 
There is no clear definition of the splicing pattern classification, but with the 
widely accepted classification, most of alternative splicing events can be 
grouped into four major patterns (Favaro et al., 2011). Figure 1-1 shows these 
four patterns and the detailed descriptions are given as follows:  
 Exon skipping: one or more exons are not included in the mature mRNA 
during the splicing process. As shown in the Figure 1-1a, two exons are 
skipped so that the mature mRNA transcript will include only exon 1 
and exon 4. 
 Alternative 5’ splice site: the splicing process uses a different 5’ splice 
site (splice donor site) as the Figure 1-1b. The alternative 5’ splice site 
can exist in either the exon region or intron region, which results in 
various transcripts formed.  
 Alternative 3’ splice site: the splicing happens with a different 3’ splice 
site (splice acceptor site) at the intron removal step. This subtype has a 
same 5’ splice site but a different boundary of 3’ splice site in the 
transcripts (Figure 1-1c).  
 Intron retention: a region that should be normally removed as an intron 
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is simply retained as part of an exon and form a part of the final mature 
mRNA. Figure 1-1d depicts an intron between exon 2 and exon 3. 
With the two neighboring exons, the retained intron forms a longer 
exon.  
Although the above classification covers most of alternative splicing events in 
genomes, it is however restricted to simple types of splicing processes. There 
are still remaining complex splicing events, which cannot be categorized into 
any of the above splicing patterns and can be a combination of multiple events 
of the above splicing processes. By classifying the alternative splicing events in 
12 metazoan species with the above simple patterns, Sammeth et al (2008) 
found out that the percentages of the exon skipping transcripts and the complex 
splicing transcripts in vertebrates were higher than those in invertebrates. In 
human genome, it has been reported that the percentage of exon skipping is the 
highest among all alternative splicing events, which accounts for around 40%. 
However, approximately 30% of total splicing events do not belong to any of 
the four basic splicing patterns but belong to more complex alternative splicing 





Figure 1-1. The four widely accepted splicing patterns (a-d). 
The boxes represent the exon regions and the lines connecting exons represent 
the intron regions. The colored thin lines represent the joining points after 
splicing.  
1.1.4 RNA splicing mechanism 
During a splicing process, introns are removed while the two selected 
neighboring exons are joined together by a spliceosome. Five small nuclear 
ribonucleoproteins (snRNPs) and a series of splicing factors are assembled 
together to form the spliceosome --- a macromolecular complex which 




Along with the evolution of different snRNPs components in the splicing 
regulatory machinery, metazoan species have two different spliceosomes while 
other eukaryotic species have only one. The two spliceosomes are U2 and U12, 
binding to U2-type introns and U12-type introns, respectively. U2-type introns 
are the major ones in metazoans and can be also found in other eukaryotic 
species while U12-type introns contribute a small fraction of all introns (Hall 
and Padgett, 1994). The snRNPs can only recognize and bind to specific RNA 
sequences, and thus the difference in the splicing machinery leads to different 
consensus regions around the splice sites (Hall and Padgett, 1994; Will and 
Luhrmann, 2005). With the aid of the splice site consensus motifs, 
bioinformatics methods/tools can therefore be applied to predict the 
spliceosome types. 
1.1.5 U2 spliceosome 
A U2 spliceosome is the common spliceosome type in all eukaryotic species, 
which is composed of various splicing factors and five key snRNPs U1, U2, U4, 
U5, and U6. The U2 spliceosome recognizes intron region that begins with 
“GT/GC” and ends with “AG”. These snRNPs join the spliceosome at different 
stages, resulting in the formation of various spliceosome complexes (Burge et 
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al., 1999). Figure 1-2 shows the four assemblies formed with different snRNPs 
during splicing from a pre-mRNA to the mature mRNA. The detailed 
description of the spliceosome complexes is as follows: 
 Complex E 
U1 snRNP binds to the 5’ splice site and U2AF (U2 snRNP auxiliary factor) 
binds to the location between the branch site and 3’ splice site. At this step, 
the length and the detailed location of the to-be-removed intron are 
determined by the spliceosome complex E.  
 Complex A 
All introns have branch sites “A”, which closely locate to the 3’ splice sites. 
At this stage, U2 snRNP specifically binds to the branch point. 
 Complex B 
The U4, U5, and U6 snRNPs form a tri-snRNP complex which binds to the 
5’ splice site and rearranges the binding site of these snRNPs, leading to U6 
snRNP instead of U1 binding to the 5’ splice site (Burge et al., 1999; Staley 
and Guthrie, 1998).  
 Complex C 
This complex is formed after the release of U1 and U4 snRNPs. In this 
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structure, the three remaining snRNPs catalyze transesterification for the 
two exons, linking the two boundaries of exons together at final stage. The 














Figure 1-2. Different stages of the U2 spliceosome complex. 
The small orange circles represent the snRNPs in forming the spliceosome 
assembly. Both blue and gray boxes represent exons and the green lines 
represent intron regions. The nucleotides in the pre-mRNA are binding 




1.1.6 U12 spliceosome 
With different snRNPs as in U2 spliceosome, U12 spliceosome consists of U11, 
U12, U4atac, U5, and U6atac snRNPs (Pan et al., 2008). The U12 spliceosome 
uniquely exists in metazoans, but accouts for only less than 1% introns. The 
splicing process in the U12 spliceosome is similar to that in U2 spliceosome but 
with the difference in the consensus sequences of introns. The U12 spliceosome 
recognizes introns with “GTATCC” or “ATATCC” at the intron start sites and 
“AG” or “AC” at the end of an intron. Unlike the U2 spliceosome, the U12 
spliceosome does not use other splicing factors for binding the U12 snRNP, 
which leads to the distance from the branch site to 3’ splice site relatively stable 
in comparison with the U2-type introns (Figure 1-3). This difference in the 
branch site location provides an opportunity to predict the spliceosome subtypes 
using bioinformatics methods.  
As shown in the Figure 1-3, U11 snRNP binds to the 5’ splice site in the 
complex E, which serves the same functions like U1 in U2 spliceosome, and 
U12 takes the role of U2. In the U12 spliceosome, U11 snRNP serves a similar 
role as U1 snRNP in the U2 spliceosome, and U12 snRNP takes the place of U2 
snRNP. They together form complex A of a U12 spliceosome. The tri-snRNP 
complex in a U12 spliceosome consists of U4atac, U5, and U6atac. The U12 
12 
 
spliceosome splices out U12-type introns. Despite being rare, the genes which 
contain U12-type introns play important roles in distinguishing related 
organisms, presenting specific genes, slowing kinetics of intron removal, and 
regulating the gene expression levels (Edery et al., 2011; Hastings et al., 2005; 
Jolma et al., 2010; Onodera et al., 2014; Padgett, 2012; Shaw et al., 2003). 
Therefore, mutations in spliceosome related genes, especially those genes 
forming the functional U12 spliceosome, would affect human biological cellular 















Figure 1-3. Different stages of the U12 spliceosome complex. 
The small orange circles represent the snRNPs forming the spliceosome 
assembly. Both blue and gray boxes represent exons and the green lines 
represent intron regions. The nucleotides in the pre-mRNA are the binding 






1.1.7 Splicing regulation 
Not only the key snRNPs play an important role in the process of intron removal, 
a series of splicing factors are also vital in regulating alternative splicing. The 
detailed role of a splicing factor in the splicing process is determined by both 
the original functions of these trans-acting proteins as well as the cis-acting 
elements where these factors bind to (Smith and Valcarcel, 2000; Wang and 
Burge, 2008; Will and Luhrmann, 2011). During the splicing process, splicing 
factor proteins can act as either repressors or activators in splicing regulation. 
The binding elements or genome regions for those trans-regulating splicing 
factors can be classified into four types of cis-acting regulatory elements: exonic 
splicing enhancers (ESE), intronic splicing enhancers (ISE), exonic splicing 
silencers (ESS), and intronic splicing silencers (ISS). Their cis-acting regulatory 
mechanisms are shown in Figures 1-4 for ESE/ISE elements & 1-5 for ESS/ISS 
elements, respectively.  
 Exonic splicing enhancer (ESE) 
An exonic splicing enhancer (ESE) is a part of exon, where an activator 
will bind to. A splicing factor binds to an ESE element will enhance 
splicing out of the neighboring intron and aids the spliceosome to 
accurately recognize the proper splice sites. This element has a 6nt motif 
in the exonic region binding with a family of proteins with long serine 
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and arginine amino acid repeats (SR proteins) (Matlin et al., 2005; Wang 
and Burge, 2008). Motifs of SR proteins contain high purine enriched 
motifs, AC-rich motifs, and pyrimidine enriched motif (Caceres and 
Hurst, 2013; Coulter et al., 1997; Fairbrother et al., 2002; Schaal and 
Maniatis, 1999). SR proteins will bind to an ESE element to promote the 
efficient binding of spliceosome elements to reduce the possibility of 
exon skipping and neighboring intron retention.  
 Intronic splicing enhancers (ISE) 
An ISE is located in intron regions, and activator proteins will bind on 
it to increase the possibility of splicing out the introns. The function of 
ISEs in splicing regulation is similar to that of ESEs. Once SR proteins 
bind to an ISE, the resulting spliceosome is able to precisely remove the 
intron where the ISE is located. The regulating regions of ISE and ESS 
are around 50-100nt, allowing effective recognition of the intron/exon 
splice sites and thus ensuring the intron removal (Fairbrother et al., 
2004). 
 Exonic splicing silencer (ESS) 
Being located in exon, an ESS will be bound by repressors, preventing 
the neighboring introns to be removed by spliceosome. It blocks proper 
recognition of the sounding splice sites and leads to alternative splicing. 
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The hnRNPs (heterogeneous nuclear ribonucleoproteins) are the most 
common repressors (Matlin et al., 2005; Wang and Burge, 2008). The 
lengths of the motifs for an ESS recognized by repressor proteins are not 
as fixed as the length of an ESE/ISE, and but most of them range 
between 4 to 18 nucleotides (Goren et al., 2006). 
 Intronic splicing silencer (ISS) 
Being located within intron regions, an ISS element will be bound by 
repressors, decreasing the possibility of removing the introns. The 
binding to an ESS or ISS increases the possibility of generation of 
transcripts being associated with exon skipping, alternative 5’ splice site, 
alternative 3’ splice site, and intron retention.  
In general, splicing results are not only determined by the functions of the 
splicing factors, but also by their binding locations. The detailed splicing 
regulatory mechanisms are very complex since the splicing results are highly 
dependent on the surrounding environment. It was reported that splicing factors 
which served as activators in normal splicing could function as repressors in 
splicing process when they bind to silencing elements (ESS/ISS), and vice versa, 
repressor proteins could act as activators when binding to enhancer regulatory 
elements (ESE/ISE) (Lim et al., 2011). In addition, some splicing factors have 
dual functions acting as both repressors and activators depending on the 
17 
 
surrounding sequence or presence of other splicing factors (Barash et al., 2010).  
As mentioned above, splicing factors and cis-regulating elements are 
indispensable in order to correctly perform splicing. Mutations in these splicing 
factors or cis-regulating elements will therefore increase dysregulations of the 




















Figure 1-4. Regulating effect of ESE and ISE elements. 
The green arrows refer means enhancement of splicing-out regulations when 
SR factors bind to an ESE/ISE. The blue broken lines refer to the spliced-out 




Figure 1-5. Regulating effect of ESS and ISS elements. 
The red curves refer to the obstruction function of the hnRNP splicing factors 
upon their binding with an ESS/ISS. The blue broken lines refer to the regions 




1.2 Alternative splicing related to pathologies 
1.2.1 Alternative splicing may lead to disease 
Mutations of genes involved in the spliceosome can lead to dysregulation of 
splicing and thus affect biological cellular processes and normal physiological 
functions. It has been reported that more than 30% of human diseases caused by 
mutations are related to alternative splicing (Lim et al., 2011). A representative 
genetic disease is Spinal Muscular Atrophy (SMA), which is caused by the 
mutations in SMN1 and modified the severity by mutations of SMN2 gene. The 
most frequent mutation of SMN2 gene happens with a single nucleotide 
mutation (840.C>T) leads to the exclusion of exon 7 during the splicing. The 
resulting exon-skipping isoform significantly down-regulates the expression of 
functional SMN protein (Brzustowicz et al., 1990; DiDonato et al., 2003; 
Sendtner, 2010). The mechanism of down-regulation of SMN expression is due 
to genomic alternation in an ESE element for splicing factors. As a result of the 
mutation/alternation, the ESE in normal genome turns to a ESS, causing 
dysregulation of splicing.  
1.2.2 Alternative splicing in cancers 
Splicing also plays an important role in people’s well-beings as studies in recent 
years show that alternative splicing is closely related to cancers. It was 
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discovered that the mutations of splicing factors often occurred in a number of 
cancers and precancerous conditions (Newman et al., 2014; Santiago et al., 2013; 
Wahbi et al., 2013). In addition to mutations in functional genes, mutations in 
the genes related to the spliceosome are commonly found in various cancers 
(Yoshida et al., 2011). Recurrent mutations of SF3B1, SRSF2, U2AF1, 
U2AF35, ZRSR2, and other spliceosome factors are discovered to be associated 
with a wide range of hematologic diseases such as Myelodysplastic Syndrome 
(MDS), Chronic Lymphocytic Leukemia (CLL), Chronic Myelomonocytic 
Leukemia (CML), Acute Myelogenous Leukemia (AML), Myeloproliferative 
Neoplasms (MPNs) (Cazzola et al., 2013; Graubert et al., 2011; Rozovski et al., 
2013). These spliceosome mutations were also identified in some solid cancers, 
including but not limited to pancreatic cancers, breast cancers and 
neuroblastomas (Ellis et al., 2012; Harbour et al., 2013; Schilling et al., 2013; 
Scott and Rebel, 2013).  
1.3 Genome-wide detection of differential splicing 
To better explore and understand possible mechanisms and pathologies of these 
splicing changes, an efficient pipeline for genome-wide splicing analysis is 
extremely desired. With the development of high-throughput technology, deep 
sequencing of alternative splicing RNA transcripts has become an important 
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method in biological research. In order to investigate all possible alternative 
splicing changes, a few bioinformatic software tools have been developed for 
analyzing RNA sequencing samples in various labs. 
1.3.1 Literature review of splicing software tools 
With the tremendous progress of next-generation sequencing technology, 
genome-wide alternative splicing events have been intensively studied in the 
recent years. Existing alternative splicing software tools were generally 
constructed with three different approaches: isoform resolution models, count-
based models, and combinatory models (Liu et al., 2014). An isoform resolution 
model uses the expression levels across different exons of a gene, and applies a 
statistical model to assemble different transcripts of the gene and estimate the 
expression levels of individual transcripts. In a count-based model, various 
transcripts of a gene are constructed based on the junction reads between 
different exons and introns. And as the name suggests, a combinatory model 
utilizes both of the above methods and combines them to perform splicing 
analysis. The representative software tools for the three models are Cufflinks, 




1.3.2 Cufflinks  
Cufflinks (Trapnell et al., 2010) is the most commonly used software tool for 
detecting differential splicing nowadays. Cufflinks is capable of identifying 
both isoform expression changes and unannotated splicing events based on 
RNA-Seq data even without annotated transcript information. In order to find 
the different kinds of splicing candidates, three programs: Cufflinks, Cuffmerge, 
and Cuffdiff are run in sequence. Firstly, Cufflinks is used in estimating the 
exact boundary of isoforms in different exon regions. Then Cuffmerge 
combines the different sample results together and Cuffdiff identifies the 
different splicing candidates in the samples with a t-test model using Jensen 
Shannon Divergence (JSD).  
Nevertheless, Cufflinks constructs isoforms based on the splicing compatibility, 
making its findings unreliable in the genes with many transcripts. Moreover, 
Cuffdiff only accepts mapping results from one mapping program called Tophat 
(Trapnell et al., 2009), an RNA-Seq read aligner software tool designed by the 
same authors. This makes the accuracy of the output highly dependent on 
Tophat. However, it has been shown in several studies that Tophat is inferior to 
several other aligners for RNA-Seq data (Dobin et al., 2013; Engstrom et al., 
2013). Although Cuffmerge can combine biological duplication samples 
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together posterior to the analysis of Cuffdiff, the time consumption for 
identifying the differentially spliced candidates will increase tremendously. 
More importantly, it often fails to effectively predict the detailed transcript 
difference. Due to the above limitations, Cufflinks cannot well identify 
comprehensive splicing changes in samples with many unannotated splicing, 
especially in cancer samples.  
1.3.3 MATS  
In comparison to Cufflinks, MATS (Shen et al., 2012) can only identify 
unannotated events for simple splicing patterns. MATS predict all the five basic 
alternative splicing patterns using a Bayesian statistical model --- Markov Chain 
Monte Carlo (MCMC). However, this method is unable to handle any complex 
alternative splicing patterns. Briefly, MATS predicts the specific exon-exon 
junction reads which are uniquely mapped to exon inclusion or skipping regions 
as candidates. After identifying the possible candidates, MATS uses a MCMC 
method to estimate the splicing differences between samples. Significantly 
changed transcripts with exon skipping are selected by estimating FDR, which 
is sampled with Fisher’s exact test. After identification of the potential splicing 
candidates, the software tool will then perform the remapping of those 
corresponding reads used for identification of the candidates. The remapping 
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can be helpful in reduction of false discovery. Thus, the splicing analysis results 
obtained by MATS are considered to be highly accurate. However, the number 
of splicing events identified by MATS is often very small and the discovered 
splicing events are limited to simple splicing patterns.  
1.3.4 MISO 
MISO predicts splicing candidates by combining a count-based model and an 
isoform resolution model (Katz et al., 2010). To estimate the differentially 
expressed isoforms, MISO utilizes the exon-exon junction reads firstly and then 
applies a linear regression model for the read counts across all exons. Using the 
exon-exon junction reads for annotated isoforms with high coverage of 200 read 
per kBs, MISO may be able to decrease the false discovery rate (FDR) 
significantly. However, MISO can also only be used for prediction of annotated 
isoform expression changes but fails to point out any unannotated splicing 
events. Furthermore, MISO can only handle simple pairwise matched 
comparison and is unable to deal with sample group-to-group comparison. 
1.3.5 Other published splicing detection software tools 
In addition to the most popular three methods, more than 10 genome-wide 
splicing analysis software tools have been published in recent years. 
 SPliceTrap  
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SPliceTrap (Wu et al., 2011) is designed for finding the alternative 
splicing events in a single sample, and thus fails to identify differential 
splicing candidates among different conditions. 
 FDM (Flow difference metric) 
FDM (Singh et al., 2011) captures the transcription difference by 
generating multiple features and using maximum mean discrepancy 
method to compare the read coverage in exons. It uses graph-based static 
models to predict candidates for splicing changes without annotation. 
FDM accept biological replicates in the selections of differential 
splicing candidates. However, it fails to filter junk meaningless regions 
and thus leads to large FDR.  
 DEXSeq 
DEXSeq (Anders et al., 2012) is designed for detecting differential exon 
usage in RNA-Seq and is known for its nice visual output. However, 
despite its usage in identifying exon skipping, DEXSeq fails to point out 
majority of the other forms of splicing changes, including isoform 
expression change and unannotated splicing cases.  
 DSGseq 
Similar to DEXSeq, DSGseq (Wang et al., 2013) is also just to identify 
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exon skipping events only. DSGseq is known to perform faster in 
detecting candidates than DEXSeq and it can also use incomplete 
annotations to analyse exon skipping events. As such, DSGseq can be 
used in multiple sample analysis. However, it does not provide any p 
value for candidate selection.  
 DiffSplice 
DiffSplice (Hu et al., 2013) is designed to detect all possible forms of 
alternative splicing patterns in both known and unannotated transcripts. 
It utilizes the number of RNA-Seq reads mapped to transcripts and 
estimate the boundaries of transcripts using reads distribution. It also 
uses graph-based model to discover the splicing events similarly as 
FDM. However, the performance is known to be inferior to other 
software tools (Liu et al., 2014).  
Other existing software tools share similar limitations: AltAnalyze (Emig et al., 
2010) can only utilize microarray data; PSGInfer (LeGault and Dewey, 2013) 
does not support biological replications; SplicingCompass (Aschoff et al., 2013) 
and SeqGSEA (Wang and Cairns, 2014) are only capable of detecting exon 
skipping events; rDiff-parametric (Drewe et al., 2013) fails to detect 
unannotated splicing changes. 
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1.4 Objectives of our analysis pipeline 
Although many software tools are available in the field of splicing detection, 
the existing ones all fail to perform well in one or a few of the situations: 
identification of complex and/or unannotated splicing events, and effective 
handling comparison for large-scale biological replicates or large-scale sample 
group-group comparison. 
 Complex and/or unannotated splicing events 
Only a limited number of software tools are capable of detecting 
unannotated splicing candidates. Cufflinks and Diffsplice are the only 
ones that are catered for splicing analysis of all the possible patterns. 
MATS can only perform splicing analysis for simple unannotated 
patterns, and the other software tools can only detect exon skipping 
unannotated changes. The complex nature of the isoform reconstruction 
model often leads to a number of biases and obstacles while predicting 
the splicing differences. The count-based model utilizing the junction 
count is suitable in genes with multiple isoforms. As more than 95% of 
human genes have splicing differences, the count-based model should 
be a suitable candidate in identifying splicing events in human genome. 
However, none of any existing count-based splicing software tools could 
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cover all the splicing patterns, all of the existing ones perform badly in 
complex patterns which cannot be classified into any of the four basic 
patterns. 
 Large-scale clinical biological replicates (sample groups) 
As the development of RNA-Seq technology provides an opportunity to 
analyse genetic related diseases, a large number of RNA/DNA-seq data 
for clinical samples have been generated world-wide and available to 
the research community. However, the analysis of the splicing 
differences in this large pool of clinical samples remains a big problem. 
To make the situation even more complex, cancer cell samples are 
known to have splicing variations from different sources and the splicing 
patterns may vary from patient to patient and from disease to disease. 
However, it is important to perform splicing analysis between two 
homogenous groups of samples e.g. a particular subtype of AML 
patients versus normal CD34+ bone morrow donors to generate 
potential common splicing regulatory mechanisms for a disease 
subgroup. As discussed above, none of the existing methods are unable 
to perform large-scale sample group-group comparison with reasonably 
high accuracy for comprehensive discovery of various splicing events 
with simple and complex patterns. Furthermore, all of the existing 
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software tools have long running time and none of them can process a 
large amount of clinical data in a reasonable short time.  
While the mechanism of alternative splicing remains largely undiscovered, 
comprehensive analysis of splicing events in tissues and clinical samples are 
extremely needed. Thus, the main goal of this thesis is to develop a sophisticate 
tool for tackling the above mentioned problems and better exploring the splicing 
events of not only annotated but also unannotated simple and complex patterns. 
The detailed objectives are as follows: 
 Development of a sophisticate splicing software tool for comprehensive 
splicing analysis 
To this end, we have developed a splicing analysis tool called 
SpliceScan, which is able to identify splicing changes between two 
group samples for both single-end and paired-end RNA-Seq data with 
high speed. Most importantly, SpliceSacn is able to identify all forms of 
splicing differences: exon skipping, intron retention, alternative 5’ splice 
site, alternative 3’ splice site, unclassified splicing in splice sites, and 
annotated isoform ratio changes. The workflow of SpliceScan will be 
explained in detail in the following chapter.  
 Application of the proposed software tools in large-scale clinical studies 
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In order to test the performance of the proposed tool SpliceScan for 
differential splicing analysis in real clinical samples, SpliceScan will be 
applied in the studies of 1) identification of all the potential differential 
splicing candidates regulated by ZRSR2 in hematological diseases 
(Chapter 3), and 2) hypoxia effects on differential splicing in MCF7 
breast cancer cell lines (Chapter 4). To evaluate the performance of the 
tool, experimental validation results are provided by the corresponding 
collaborators. 
The results of the above studies reveal that, SpliceScan not only accurately 
identifies more differential splicing events, but also accelerates the process of 
understanding pathologies of splicing related disease and its regulatory function 
in different conditions. By comparing the splicing differences between the 
samples and the controls, SpliceScan is capable of identifying the differentially 
spliced transcripts, which would be helpful in providing better insight into 
understanding the diseases.  
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2 Chapter 2. Development of a computational tool 
for discovery of differential splicing 
To fulfill the requirement for analyzing complex splicing events in both 
biological and clinical research, I have developed the SpliceScan, a software 
tool for discovery of differential alternative splicing. Utilizing RNA-Seq data, 
the computational tool aims to identify various splicing candidates between 
samples in different groups, including unannotated splicing events and 
alternative usage of isoforms. In the software, a model based on reads counting 
was utilized which is focused on the counts of reads crossing exon-intron 
boundary as well as spanning an intron or linking any two non-neighboring sites. 
SpliceScan uses a parameter called Splice Index (SI) to evaluate differential 
splicing between difference samples. Furthermore, SpliceScan utilizes the 
following two criteria: 1) p value derived from Fisher’s exact test using read 
counts, and 2) difference in SI values between the samples. In the first round of 
splicing analysis, SpliceScan focusses on detecting splicing events for 
individual samples, while identification of differential splicing events between 
two groups of samples is performed at the second step. The group comparison 
is focused on finding common splicing changes between two groups such as 
tumor versus normal samples, or treatment versus control samples. In the 
analysis, SpliceScan can process all the samples at the same time using multiple 
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threads, which largely decreases the computational time in splicing analysis. 
SpliceScan also applies both p values and difference in SI to reduce the false 
discovery rate. Furthermore, SpliceScan utilizes the background distributions 
for more accurate prediction of differential splicing. The background 
distribution is obtained by comparing two samples from the same group for 
differential splicing. 
2.1 Workflow of SpliceScan software 
SpliceScan consists of several bioinformatics modules. Figure 2-1 shows the 
workflow of SpliceScan for splicing analysis. As the inputs for the tool, 
SpliceScan will require RNA-Seq sequencing data of samples in both group 1 
and 2. The software tool permits both raw data in the fastq format and mapped 
files in the BAM/SAM format as inputs. Mapping is an optional step. However, 
mapping of RNA-Seq data is the most critical step for successful splicing 
analysis. Mapping errors can inflame the false discovery enormously. Detailed 
description about mapping is given in Section 2.2. 
Genome information such as version of a known genome or GTF/GFF file 
should also be inputted into the software. The details for library preparation are 
illustrated in Section 2.3. 
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When all input files are provided, SpliceScan will initiate the first round of 
analysis. At this analysis round, the following two core analysis modules will 
be undertaken: 1) read classification of mapped reads and 2) calculation of SI 
for each splice site. For intron retention, an additional analysis module will be 
performed to make sure that the retained intron is covered sufficiently with 
mapped reads to reduce possible false mapping at the junctions. Detailed 
description about these analysis modules is given in section 2.4. 
The second round of analysis is the group-to-group comparison for evaluation 
of differential splicing. There are two key analysis modules at this round: 1) 
determination of SI difference (ΔSI) and significant level (p value) between any 
two samples from the two different groups, and 2) determination of SI 
difference (ΔSI) and significant level (p value) between any two samples from 
the same groups as background. The detailed description of this analysis round 
modules can be found in Section 2.5.  
In Section 2.6, I will discuss statistics used in pairwise comparison as well as 
group comparison for discovery of differential splicing. The description of the 




Figure 2-1. Workflow of splicing analysis in SpliceScan. 
The colors in the figure represent the types of files: orange files are input files, 
green boxes represent the output results, purple diamonds represent the 
judgment steps in the software, and blue rectangles are steps in the software 
analysis. The steps in the red dash rectangle are the first round analysis and the 




Mapping step is an optional function in the SpliceScan software.  
In analysis of RNA-Seq data, the accurate sequence mapping is highly 
demanded and is a decisive factor for the accuracy of the following steps in 
calling differential splice sites. SpliceScan can start the analysis with mapped 
results or the unmapped raw fastq files. One can perform mapping by using 
other software tools or using the default software tool in the SpliceScan.  
In the analysis of differential splicing candidates with SpliceScan, the quality of 
mapping results will affect the results since the SpliceScan have relative high 
sensitivity in the identification of differential splicing candidates. To obtain the 
accurate differential splicing candidates, a combined use of different mapping 
tools will be helpful to reduce improper mapping results. In the study of ZRSR2 
mutation in MDS (Chapter 3), we mapped the sequence files with a combination 
of Bowtie (Langmead et al., 2009) and BLAT (Kent, 2002) as follows: 
 Raw sequence files firstly mapped to Refseq annotated transcriptome 
and whole genome sequence and with Bowtie software.  
 The mapped results of Bowtie for transcriptome mapping were 
converted to normal genomic location, enabling the merge of the 
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mapping results from both libraries (transcriptome & whole genome). 
 Then unmapped reads for both transcriptome and whole genome at the 
first mapping step were realigned with BLAT.  
 After getting the BLAT results, both mapping result from Bowtie and 
BLAT were merged and converted to sorted BAM format.  
The complex way of mapping can decrease false discovery candidates; however, 
the time for running might be quite long and very inconvenient to use. Among 
all existing RNA-Seq mapping software tools, STAR (Dobin et al., 2013) was 
reported as the most appropriate alignment tool in splicing analysis (Engstrom 
et al., 2013). STAR has a very good sensitivity and relative low false discovery 
rate in sequencing mapping. Importantly, the running time used for running 
STAR is at least 10 times shorter than the one for Bowtie+BLAT. Thus, 
SpliceScan uses STAR as the default mapping software for the raw sequence 
file (fastq or zipped fastq format) in differential splicing analysis. In the study 
of hypoxia regulating alternative splicing (Chapter 4), SpliceScan analyzed the 




2.3.1 Library selection 
SpliceScan uses the annotated splice sites to globally check all unannotated 
splicing changes and isoform ratio changes between groups. Therefore, the 
annotation is the necessary requirement for the differential splicing analysis 
with SpliceScan. In this software tool, we have already built mapping libraries 
of the commonly used genome versions, containing hg38 library with UCSC 
gene annotation, hg19 library with UCSC gene annotation, hg19 library with 
Ensemble annotation, mm10 library with UCSC gene annotation, and mm9 
library with UCSC gene annotation (Table 2-1).  
A new genome version provides more transcripts, which may improve the 
mapping results, and give better results in splicing analysis. As presented in the 
Table 2-1, the amount of detectable annotation difference between mm10 and 
mm9 is around 1%, but the difference between hg38 and hg19 reaches 5%. 
Therefore, different selection of genome version will lead to difference in the 
calculation of splicing candidates. As a result, differential splicing analysis can 
only be performed for the samples mapped with the same genome version.  
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# of annotated 
introns 
# of annotated 
splice sites 
hg19 Ensembl 558,865 991,200 
hg38 UCSC 228,357 420,376 
hg19 UCSC 211,123 397,431 
mm10 UCSC 200,051 382,360 
mm9 UCSC 196,916 381,746 
2.3.2 Library construction 
If the mapping libraries are not in the provided list, then the program requires a 
GTF/GFF format of annotation. The GTF/GFF file is the combination of 
annotated transcript information in the genome, which can be downloaded from 
public database or provided by the users. SpliceScan will generate two files 
during the library construction: 
 For annotated introns 
SpliceScan uses the exon regions in every transcript and gets the spliced 
intron based on this provided information. Since many transcripts have 
the same splicing events, the software rebuilds the library by removing 
the duplicated splicing events. 
 For annotated splice sites 
Similarly, the file for annotated splice sites is constructed by removing 
the duplicated splice sites in the annotated introns.  
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2.4 Reads classification 
Since improper mapping results will affect splicing analysis a lot, SpliceScan 
will filter the mapping reads with insertion, deletion, and soft clip. During the 
analysis, SpliceScan generates a report for the reads, including the number of 
used reads, the number of filtered reads, and the percentages of various reads. 
If the reported filtering percentage is more than 20%, the sample may not be 
properly prepared, and it is better to check if there is any problem with the 
qualities of the reads. This is important as without proper source, the resulting 
splicing analysis will not be accurate as well and this leads to large number of 
wrongly reported differential splicing candidates in turn.  
SpliceScan utilizes location and cigar values from the complete mapped reads 
to calculate the splicing candidates with constructed library annotation files. 
Based on the mapped results, SpliceScan classifies the mapped reads into five 
different groups based on their spans and locations around the annotated splice 
sites (Figure 2-2). 
 Consciously complete reads. 
This group contains the reads that are totally mapped to the long 
continuous region without any span in sequence. There is no annotated 
splice site located at the mapped region in these reads.  
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 Annotated exon-exon junction reads 
This group contains the reads whose spanning region is annotated. All 
reads in this group contain the cigar value “N” and cross at least two 
annotated splice sites to form an annotated intron. These reads should 
be observed in the two annotated exon regions with at least four base 
pairs.  
 Unannotated exon-exon junction reads 
This group of reads are similar to the annotated exon-exon junction 
reads, except that their spanning intron does not exist in the annotated 
library.  
 Exon-intron junction reads 
These exon-intron boundary reads might also be classified to exon-exon 
junction reads if they contained spans (cigar value contains “N”). All 
reads in this group are unannotated mapped cases, which shows 
differential splicing when compared to the library. The exon-intron 
junction reads are required to cross the annotated splice site and reads 
are consciously mapped at least four base pairs (“M” character in cigar) 
in both the exon and intron regions.  
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 Rest mapped reads.  
The remaining reads which do not belong to the four types above will 
not be used in identifying splicing candidates, but will be further 
explored in intron retention coverage and calculation.  
A summary of the different groups of reads will be generated in the analysis and 









2.5 Identification of potential splicing candidates 
The four basic alternative splicing patterns, namely exon skipping, alternative 
5’ splice sites, alternative 3’ splice sites, and intron retention, only compose 70% 
of alternative splicing events in human. The percentage for unclassified 
complex patterns in clinical samples is even higher, especially in the case of 
cancer samples.  
In SpliceScan, SI values are used in estimating the percentage of these spliced 
reads in both the annotated isoform transcripts and unannotated splicing events 
for every splicing pattern. To exhaustively analyze both the simple splicing 
patterns and the complex splicing patterns, SpliceScan uses different 
classification patterns to find out differential splicing events. The SI calculation 
for globally alternative splicing, exon skipping, alternative 5’splice site, 
alternative 3’splice site, intron retention and isoform ratio changed events will 
be explained in detail in the following pages. 
2.5.1 Globally unannotated splicing 
The complex splicing transcripts as shown in Figure 2-3 do not belong to any 
of the traditional basic splicing patterns. In order to analyse all the splicing 
changes in genomes, SI value is used to evaluate the percentage of unannotated 




Figure 2-3. Complex splicing events which do not belong to four basic 
splicing patterns. 
E1, E2, E3, and E4 represent the exons in these transcripts. I1, I2, and I3 
represent introns in these transcripts. 5’ and 3’ above indicate the direction of 
transcripts. The I2 of transcript 1 has an alternative 3’ splice site when compares 






Using the translation details in the library, a list of annotated splice sites is 




N(normal annoated splicing counts) + A(unannotated splicing counts)
× 100 
Figure 2-4 gives an example of the annotated 5’ splice sites and the mapped 
reads used for calculating the SI value. The normal splicing mapped reads and 
the unannotated splicing mapped reads are distinguished by whether they are 
annotated in the library. Based on read classification in the previous section, 
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normal annotated splicing reads are used for calculating the SI values for the 
splice sites. There are three different types of unannotated reads: 
 Junction reads that span exon-intron boundary site cross the given 
annotated splice site (red reads in Figure 2-4). 
 Unannotated exon-exon junction reads which span from one annotated 
splice site in one transcript to an annotated splice site in another 
transcript (orange reads in Figure 2-4). 
 For splice sites located at the end of an exon, unannotated exon-exon 
junction reads which span from the 5’ annotated splice site to an 
unannotated 3’ site are used for calculation. If the splice site is located 
at the start of an exon, unannotated exon-exon junction reads which span 
from the 5’ unannotated splice site to the annotated 3’ splice site are 
used for calculation (pink reads in Figure 2-4). 
In SpliceScan, the globally unannotated splicing candidates are identified 
by summarizing all the changes in the annotated splice sites. With the identified 
globally unannotated splicing candidates, the potential complex splicing 
candidates can be discovered as follows.  
1) The splice sites which can be identified with globally unannotated splicing 
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change but not discovered in any of the four basic patterns. 
2) The splice sites which could be identified with globally unannotated splicing 









Figure 2-4. SI calculation for candidates with globally unannotated splicing. 
The 5’ and 3’ in the transcripts indicate the direction of the transcripts. Green 
splicing reads indicate normal exon-exon reads, which map to transcript 1 and 
span the annotated intron. Blue splicing reads are the reads span the annotated 
intron in the library of transcript 2. Red reads indicate unannotated exon-intron 
junction reads that cross the annotated splice sites and are used to identify 
unannotated intron retention cases. Orange splicing reads refer to unannotated 
exon-exon junction reads with the annotated 5’ splice site and 3’ splice site 
transcripts, which are used to identify exon skipping events. Pink splicing reads 
refer to junction reads, which contain an unannotated 3’ splice site and are used 





2.5.2 Exon skipping 
During the splicing process from pre-messenger RNA to mature RNA, the 
spliceosome removes a long “intron” which contains one or several normal 
exons, and results in a truncated mature RNA. As shown in Figure 2-5, the exon 
skipping reads contain normal 5’ splice site and 3’ splice site, but the spanning 
details cannot be found in the library. All exon skipping reads that contain 
normal 5’ and 3’ splice site in the same transcripts are selected from unannotated 













SI of exon skipping (%) =
2A
N1 + N2 + 2A
× 100 
 
Figure 2-5. SI calculation for candidates with exon skipping. 
The 5’ and 3’ in the transcripts indicate the direction of the transcripts. The 
purple exon skipping reads refer to the junction reads that exclude at least one 
exon in comparison with the annotated transcript. Green normal reads refer to 
the junction reads that span the annotated intron in the annotation library. A: 
Reads count of these unannotated exon-exon junctions reads with the annotated 
5’ splice site and 3’ splice site in one transcript. N1: Reads count of these 
annotated exon-exon junctions reads which contain the same 5’ splice site as 
exon skipping event. N2: Reads count of these annotated exon-exon junctions 




2.5.3 Alternative 5’ splice site  
In SpliceScan, the alternative 5’ splice sites refers to the splicing candidates 
with an annotated normal 3’ splice site but without an annotated 5’ splice site, 
which leads to failure in forming an annotated intron. In Figure 2-6, the reads 
used for calculating SI of alternative 5’ splice sites are selected from 
unannotated exon-exon junction reads and annotated exon-exon junction reads. 
2.5.4 Alternative 3’ splice site 
Similar to the definition of alternative 5’ splice site, the alternative 3’ splice site 
refers to the candidates with unannotated 3’ splice sites compared to the 
annotated intron (Figure 2-7). The formula used for estimating the component 
of alternative 3’ splice site in the transcripts is the same as that of alternative 5’ 



















Figure 2-6. SI calculation for candidates with alternative 5' splice site. 
The 5’ and 3’ in the transcripts indicate the direction of the transcripts. Pink 
alternative 5’ splice site reads refer to the junction reads that contain an 
unannotated 5’ splice site. Green normal reads refer to the junction reads that 
span the annotated intron in the library. A: Reads count of these unannotated 
exon-exon junctions reads with the annotated 3’ splice site. N: Reads count of 









Figure 2-7. SI calculation for candidates with alternative 3' splice site.  
The 5’ and 3’ in the transcripts indicate the direction of the transcripts. Pink 
alternative 3’ splice site reads refer to junction reads which contain an 
unannotated 3’ splice site. Green normal reads refer to junction reads that span 
the annotated intron in the annotation library. A: Reads count of these 
unannotated exon-exon junctions reads with the annotated 5’ splice site. N: 
Reads count of these annotated exon-exon junctions reads which contain the 




2.5.5 Intron retention 
Intron retention refers to the phenomenon where the original intron regions are 
kept during the intron removal process and a real intron retention event should 
be covered with mapped reads all over the region. Figure 2-7 shows the intron 
retention candidates with the definition in our pipeline. The exon-intron 
junction boundary reads (red color in the figure) on both sides and the normal 
exon-exon junction boundary reads (green color in the figure) are used to 
evaluate the competence of intron retention in all the transcripts. The formula 
for calculating SI of intron retention cases is listed in Figure 2-8. In intron 
retention analysis, only introns that pass all the following requirements are 
reported as the potential intron retention candidates in SpliceScan: 
 More than 4 total reads count (N+A1+A2>4).  
 Reads count of exon-intron junction boundary on both sides of the 
intron should be more than 0 (A1>0 & A2>0).  
 More than 95% of the intron region must be covered with mapped 
reads. And these contain exon-intron junction boundary reads and 
intron mapped reads.  
 Comparing to the normal exon-exon junction reads, the retention regions 
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must have at least an average of 10% depth.  
 
 
SI of intron retention(%) =
A1 + A2
2N + A1 + A2
× 100 
Figure 2-8. SI calculation for candidates with intron retention.  
The 5’ and 3’ in the transcripts indicate the direction of the transcripts. The 
intron retention reads in red refer to exon-intron junction reads across the 
annotated splice sites. The normal reads in green refer to the normal exon-exon 
reads that span the annotated intron in library transcript. A1, A2: count of 
junction reads across the annotated 5’ and 3’ splice site. N: Reads count of 




2.5.6 Isoform ratio change 
Many transcripts have a unique set of annotated introns, and are therefore very 
different from their isoforms. The junction reads count of these introns can then 
be used to estimate the isoform ratio using the following formula.  
SI (%) =
N (normal reads count in transcript)
∑ N (Total normal intron)
× 100 
The total normal count in the above formula is the total number of normal reads 
with the same splice sites in the gene. Figure 2-9 shows the reads used for 
calculating the SI of transcripts and all reads in this part are normal exon-exon 
junction reads. However, it is impossible to calculate the exact ratio for the 
















Figure 2-9. SI calculation for candidates with isoform ratio change.  
Green reads refer to normal junction reads which span the unique intron in 
transcript 1, and N1 represents its reads count. Blue reads refer to normal 
junction reads which span the unique intron in transcript 2, and N2 represents 














2.6 Differential splicing analysis 
SpliceScan utilizes different methods to identify differential splicing candidates 
based on the sample size of the biological replications. The three methods in 
SpliceScan are: Fisher’s exact test for RNA-Seq with small sample size, T-test 
serves as an alternative for sample size smaller than 30, and Mann–Whitney U-
test for large amount of sample data. All the above tests output p values which 
serves as an identification index. The method to be used is open for selection by 
users. 
2.6.1 Fisher’s exact test for one to one comparison 
In certain studies, the functional unannotated splicing pattern or the isoform 
ratio is significantly different between groups. To make full use of the RNA-
Seq data and reduce the side effects from sample difference, one to one 
comparison instead of the mean value is used in estimating differential splicing 
between groups.  
For any two samples, ∆SI is used in evaluating the differential splicing between 
samples and FDR (false discovery rate) from the Fisher’s exact test is used in 
estimating significance level of the results. ∆SI is obtained by the SI value of 
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the treatment sample minus that of the control sample. The formulas for 
differential splicing analysis and Fisher’s exact test are listed in Table 2-2.  
Moreover, the calculated p values are adjusted with the R package “stat” to get 
the FDR values (R Core Team, 2013) as the splice detection is genome-wide. 
And only candidates with more than one significant differential splicing in the 
analyzing process will be reported in SpliceScan. The significance settings can 
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∑ Ns1 − Ns1 ∑ Ns2 − Ns2
) 
A1s1 A2s1⁄ : Unannotated junction reads in sample 1 and 2. 
Ns1 Ns2⁄ : Annotated normal splicing reads count in sample 1 and 2. 
∑ Ns1 ∑ Ns2⁄ : The total annotated exon-exon junction reads count in splicing 




): The matrix for calculating fisher’s exact test in the splicing pattern. 











2.6.2 T-test comparisons 
If the sample size of both of the groups is larger than 10, the one to one 
comparison method will no longer be feasible as the total combination of groups 
grows to hundreds. It is known that the comparison method using fisher’s exact 
test results in prolonged processing time and occupies enormous computational 
resource when the samples are very large. Therefore, for sample size larger than 
10 but smaller than 30, t-test comparison serves as a good choice in identifying 
differential splicing candidates between the two groups.  
SpliceScan uses paired two-sided t-test in the comparison analysis. For the 
undetectable candidates or those with very small junction reads (unannotated 
count+ normal count<5), the SI values set to zero. In this way, all the splicing 
candidates are assigned with specific SI values to estimate the percentage of 
splicing events. Here, the difference in mean between the two groups and the 
adjusted FDR ratios are used in identifying splicing difference. The p values 
from t-test are used for detecting differential splicing between Group A and B 




t − test (p value) =
SIA̅̅ ̅̅ − SI̅B
√
(nA − 1)SA
2 + (nB − 1)SB
2









SIA̅̅ ̅̅  , SIB̅̅ ̅̅ : The mean SI values in Group A, Group B. 
nA , nB: The number of samples in Group A, Group B.  
SA
2  , SB
2: The variance in Group A, Group B. 
 
The null hypothesis is setted as: the mean of Group A equals to the mean of 
Group B. Similarly, the calculated p values for all the candidates will also be 
adjusted using “p.adjust” in R. In this way, SpliceScan finds the potential 
differential splicing candidates with ∆SI and FDR values.  
2.6.3 Mann–Whitney U-test 
SpliceScan can also deal with big amount of RNA-Seq data and identify the 
splicing differences between samples. Since for hundreds of samples, fisher’s 
exact test takes enormous time and t-test is not so well performed, Mann–
Whitney U-test is used here to find out the differential splicing candidates. In 
SpliceScan, Mann–Whitney U-test is used when sample size is bigger than 30. 
The Z score is calculated as follows: 
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u − test (Z score) =











SIA̅̅ ̅̅  , SIB̅̅ ̅̅ : The mean values of SI in Group A, Group B. 
nA , nB: The number of samples in Group A, Group B.  
SA
2  , SB
2: The variance in Group A, Group B. 
 
Z score represents the significance level of the difference between the two 
groups. By comparing the calculated value with reference value, SpliceScan 
then decides if the splicing differences between the two groups are significant. 
Only candidates with the required significance level and ∆SI values are reported 
as the potential differential splicing candidates.  














Table 2-3. Correlation between Z score and p value 
Z score p value 
<-2.58 <0.01 






Z=2.58, Z=-2.58 equals to p=0.01 
Z=-1.96, Z=1.96 equals to p=0.05 
Z=-1.65, Z=1.65 equals to p=0.1 
It is known that Mann-Whitney U-test takes the least computation time among 
the three tests and it performs well in identifying candidates with relatively 
small but stable splicing changes. Fisher’s exact test not only identifies 
differential splicing candidates between groups but also identities specific 
splicing candidates from one or several samples. However, the detailed 
comparison results of Fisher’s exact test come at a cost of prolonged running 
time. And for sample size smaller than 30, t-test serves as a good choice for 
identifying the common differential splicing candidates.  
2.6.4 Final output 
At the end of splicing analysis, a final output file will generated by SpliceScan 
which includes the location of the differential splicing events, their splicing type, 
∆SI and FDR values (or significant level from Z score). A summary table for 
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the number of significant differential splicing candidates in different splicing 
patterns will also be available. 
2.7 Evaluation of SpliceScan by software tools 
comparisons 
To evaluate the performance of SpliceScan, we compared our method with 
Cufflinks, MATS, and MISO respectively on the Linux platform. The 
experimental data setup used for the evaluation and comparison of various 
methods will be described in Chapter 3. 
By looking at the programs’ log files, the analysis time and CPU time for the 
four software tools are recorded and presented in Table 2-4. It should be noticed 
that the analysis time for MATS is much longer than the other software tools as 
MATS only supports single thread. And despite very high resource usage, 
splicing analysis in Cufflinks and MISO take much longer time than SpliceScan. 
The comparison of SpliceScan with the three prevalent software tools indicates 
that SpliceScan is capable of doing differential splicing analysis in relatively 
short time with minimal resource usage. And this makes SpliceScan a good 





Table 2-4. System time of the four software tools 
 
Software Analysis time (min) CPU time (min) Threads 
Cufflinks 2464 121628 50 
MATS 16604 16604 1 
MISO 2563 116731 50 
SpliceScan 106 584 161 
1. Threads in SpliceScan ≤ number of samples 
 
In the ZRSR2 study (Chapter 3), 11 splicing events are reported in SpliceScan 
and validated through experiments. To test if these splicing events can be 
commonly identified in other software tools, the differential splicing candidates 
obtained by the other three software tools are selected as follows: 
Cufflinks: By filtering the “splicing.diff” output file, 4225 genes with “OK” 
status are selected. 
MATS: Without any filtering, the final output folder contains 2841 differential 
splicing genes.  
MISO: MISO processes the dataset with 64 pairwise comparisons. In each 
comparison, any part of the gene with |Δ Ψ| >10 and bayes factors >10 is 
identified as differential splicing. 4827 genes are collected in this approach. 
The following table summarizes the detection of the validated genes in the four 
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software tools. As shown in Table 2-5, not a single of these candidates can be 
commonly predicted by all the software tools although 10 out of the 11 genes 
identified by SpliceScan can be also predicted in at least one of the other 
software tools. Furthermore, intron retention in DOCK2 is only identified by 
SpliceScan. As such, we believe that SpliceScan serves as a superior splicing 
analysis software tool with a higher accuracy. 
 
Table 2-5. Identification of validated genes in four software tools 
Validation Splicing pattern SpliceScan Cufflinks MATS MISO 
CAPN1 Intron retention Y Y Y   
MAPK1 Intron retention Y Y   Y 
MAPK9 Intron retention Y Y   Y 




Y   Y Y 
UFD1L Intron retention Y Y     
PTEN Intron retention Y   Y   








Y     Y 
DOCK2 Intron retention Y       
Total - 11 4 6 5 




3 Chapter 3. Identification of splicing events with 
ZRSR2 mutation  
3.1 Introduction 
3.1.1 Background 
Myelodysplastic Syndrome (MDS) is a disease caused by the disorders of the 
hematopoietic stem cell in the bone marrow. It was reported that mutations in 
splicing factors can be detected in 40-80% of the MDS patients (Rozovski et al., 
2013). Recurrent mutations of spliceosome genes for MDS patients include 
SF3B1, SRSF2, U2AF1, and ZRSR2.  
In the study of SF3B1 mutation in CLL, Cazzola pointed out that SF3B1 binds 
to the branch site and regulates the 3’ splice site during the intron removal 
process (Cazzola et al., 2013). It has been reported that SRSF2, a key component 
of spliceosome, functions as a splicing enhancer by binding to the GGNG 
(N=A/C/G/T) motif region. Analyzing the clinical AML RNA-Seq samples, it 
has been found that recurrent mutations in SRSF2 lead to a change in binding 
domain, and thus untenable SRSF2 to bind with the GGNG motif, resulting in 
higher possibility of exon skipping (Kim et al., 2015). 
ZRSR2, which encodes an essential splicing factor for U2 spliceosome and U12 
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spliceosome, is frequently mutated in MDS patients (Thol et al., 2012; Yoshida 
et al., 2011). However, the functional role of ZRSR2 mutation in the pathology 
of MDS remains largely unknown. 
Recently, it was suggested that the spliceosome could be a relevant therapeutic 
target (Quidville et al., 2013). From the medical point of view, it would be 
meaningful to establish the connections between the mutations and these 
cancers, as this helps in developing novel targeted therapy for cancer. 
3.1.2 Objectives  
 Establishment of the connection between ZRSR2 mutation and 
differential splicing 
In this project, SpliceScan analyzed the RNA-Seq data from MDS 
clinical samples with ZRSR2 mutation and ZRSR2 knockdown TF-1 
cell lines. By comparing the splicing events in clinical samples with 
ZRSR2 mutation and the ones without ZRSR2 mutations, and 
analyzing the ZRSR2 knockdown samples with the wild type ones, 
SpliceScan was able to comprehensively identify the differential 
splicing events/genes, which is related to ZRSR2 knockdown. 
 Potential ZRSR2 roles in the U2 and U12 spliceosome  
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Splicing factors are key component in spliceosome assembly and play 
an indispensable role in the splicing process. One of the primary 
objectives in this study is to explore the possible ZRSR2 functions in 
spliceosome machinery. 
 The function of ZRSR2 in U2 and U12 spliceosome 
ZRSR2 exists in both the U2 and U12 spliceosome (Singh and Cooper, 
2012). All differential splicing events are thus classified into two groups 
based on the type of the regulating spliceosome, which can either be U2 
spliceosome or U12 spliceosome. We want to investigate if the splicing 
changes caused by ZRSR2 mutation in the two spliceosomes are similar 
or not.  
 The GO analysis of differential splicing genes in MDS 
While the function of ZRSR2 mutation in the pathology of MDS 
remains largely unknown, GO enrichment analysis of differentially 
spliced genes could help us to identify the potential regulating functions 




3.2 Method and Materials 
3.2.1 Sample summary 
To explore the function of ZRSR2 in MDS, 16 clinical samples with the 
following genotypes are used: 1) 8 MDS patients with ZRSR2 mutation, 2) 4 
MDS patients without ZRSR2 mutation, 3) 4 samples with normal bone marrow. 
Clinical details about the samples are listed in Table 3-1.  
Figure 3-1 mutation positions of ZRSR2 in the 8 MDS samples. The 8 mutations 
include 5 nonsense mutations and 3 deletion of 1bp in the nucleotides. Nonsense 
mutation changes normal amino acid to a terminal codon and the 1bp deletion 
changes the amino acids after this mutated position during the protein 
translation. All the 8 mutations in this study lead to dysfunction of ZRSR2 
protein and loss of function of ZRSR2.  
Apart from the clinical MDS ZRSR2 mutation samples, TF-1 AML cell line 
samples with ZRSR2 knockdowns are also used to further study the functions 
of ZRSR2. The knockdown effectiveness of samples is shown in the Figure 3-
2. RNAs from clinical samples and cell line samples were collected and 
sequenced by HiSeq 2000 (Illumina) with 100+ million paired-end reads of 
100bp for each sample (Table 3-2).  
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Table 3-1. Clinical samples used for ZRSR2 study 
 






Mutant 1 MDS yes C892T3 Q298X5 
Mutant 2 MDS yes G301T E101X 
Mutant 3 MDS yes A241T K81X 
Mutant 4 MDS yes 81delA4 K28fs6 
Mutant 5 MDS yes C883T R295X 
Mutant 6 MDS yes C700T Q234X 
Mutant 7 MDS yes 1271delG G424fs 
Mutant 8 MDS yes 735delC P245fs 
Wild type 1 MDS no   
Wild type 2 MDS no   
Wild type 3 MDS no   
Wild type 4 MDS no   
Normal 1 Remission1 BM no   
Normal 2 Normal BM2 no   
Normal 3 Normal BM no   
Normal 4 Normal BM no   
 
1. Remission: The Normal 1 sample is from the cured MDS with ZRSR2 
mutation. The RNA-Seq at disease stage is “Mutant 7” in the sample list.  
2. Normal BM: The sample collected from normal bone marrow. 
3. C892T: In ZRSR2 mRNA 892nt site, the normal nucleotide C mutated to T. 
4. 81delA: In ZRSR2 mRNA 89nt site, the normal nucleotide A is deleted. 
5. Q298X: The translation of ZRSR2 protein stops at the 298 amino acid point 
with the mutation of C892T. 





Figure 3-1. Mutation sites of the 8 samples in ZRSR2 protein.  
Mutations with red color are nonsense mutations and blue are frame shift 
mutations with 1bp deletion. “1” and “482” represent the start and end site of 
ZRSR2 protein. “ZF”,”RRM”,”RS” are the functional domains for protein 
binding and interaction with other sequences. 
 
 
Figure 3-2. Duplicated experiments were performed with one scrambled control 
and two shRNA vectors for each experiment. 




3.2.2 Differential splicing analysis 
In this study, Bowtie + BLAT were applied to perform the mapping with the 
hg19 genome. By selecting UCSC hg19 library, SpliceScan discovers the 
differentially spliced candidates with one-to-one pairwise comparisons using 
Fisher’s exact test. Table 3-2 summarizes the reads used of 16 clinical samples 





Table 3-2. Reads stats of RNA-Seq samples for SpliceScan 
Sample 
name 
Sample information # of mapped 
reads 
# of I/D/S 
reads 
% of used 
reads 
Mutant 1 ZRSR2 mutant1 148,917,172 14,535,107 90.2 
Mutant 2 ZRSR2 mutant 142,158,834 14,107,553 90.1 
Mutant 3 ZRSR2 mutant 152,893,472 15,028,475 90.2 
Mutant 4 ZRSR2 mutant 171,039,898 17,643,292 89.7 
Mutant 5 ZRSR2 mutant 141,420,572 14,357,445 89.8 
Mutant 6 ZRSR2 mutant 142,434,124 14,352,862 89.9 
Mutant 7 ZRSR2 mutant 177,001,540 20,046,414 88.7 
Mutant 8 ZRSR2 mutant 149,936,842 16,083,400 89.3 
Wild type 1 ZRSR2 WT 207,936,640 20,540,090 90.1 
Wild type 2 ZRSR2 WT 168,509,792 17,295,873 89.7 
Wild type 3 ZRSR2 WT 140,012,304 13,155,220 90.6 
Wild type 4 ZRSR2 WT 181,240,136 22,883,388 87.4 
Normal 1 Normal BM 149,784,402 16,715,649 88.8 
Normal 2 Normal BM 144,767,378 19,609,477 86.5 
Normal 3 Normal BM 153,664,804 14,983,429 90.2 
Normal 4 Normal BM 159,423,876 14,639,157 90.8 
control_1 Scrambled control 132,445,382 9,148,411 93.1 
control_2 Scrambled control 157,626,398 9,407,446 94 
ZRSR2 
sh1_11 
knockdown cell line  140,677,162 9,637,110 93.1 
ZRSR2 
sh1_22 
knockdown cell line  141,811,868 8,933,582 93.7 
ZRSR2 
sh2_1 
knockdown cell line  153,076,048 10,096,725 93.4 
ZRSR2 
sh2_2 
knockdown cell line  133,162,848 8,323,053 93.7 
1: Sample ends with “_1” refer to the sample from experiment 1.  






Based on their phenotypes, the samples are classified into three groups: MDS 
patients with ZRSR2 mutation (MT), MDS patients with WT ZRSR2 (WT), 
normal bone marrow controls (NC). In the second round of SpliceScan analysis, 
the comparisons are performed between these groups: 
 Group comparison: ZRSR2 MT versus ZRSR2 WT 
The 8 samples from MDS patients with ZRSR2 mutation (MT) are 
compared to 4 samples from MDS patients with WT ZRSR2 (WT). 
SpliceScan performs 32 (8x4) individual comparisons for pair-wise 
analysis with any two samples and one sample from each group.  
 Group comparison: ZRSR2 MT versus NC 
The group comparison contains 8 samples from MDS patients with 
ZRSR2 mutation (MT) against to 4 samples from normal bone marrow 
controls (NC). A total number of 32 comparisons are undertaken by 
SpliceScan. 
 Group comparison: ZRSR2 MT versus ZRSR2 C 
Both the 4 MDS patients with WT ZRSR2 and 4 samples from normal 
bone marrow donors can be grouped as the control samples for ZRSR2 
wildtype (ZRSR2 C) regardless of being MDS patients or healthy donors. 
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When comparing the splicing analysis results between 8 MDS patients 
with ZRSR2 mutation and the ZRSR2 wild type controls (4+4 samples), 
SpliceScan performs 64 individual comparisons to find out the 
differential splicing events between the two groups. 
 Group comparison: ZRSR2 WT versus NC 
This group comparison was performed between the two ZRSR2 WT 
controls from 4 MDS samples with ZRSR2 WT and 4 normal bone 
marrow donors. The 16 pairwise comparisons between the two groups 
will be used as background for evaluation of the effects of ZRSR2 loss-
function mutations on splicing events.  
 Group comparison: shRNA versus scrambled  
The two ZRSR2 knockdown TF-1 samples are compared with their 
respective scrambled controls (control_1/control_2). 
 Group comparison: scrambled versus scrambled 
As background for evaluation of ZRSR2 knockdown effects on splicing 




3.2.3 Intron type classification  
Splicing process in mammals is controlled by two spliceosomes, the U2 
spliceosome and U12 spliceosome. The two spliceosomes use different snRNPs 
in the process of intron removal, leading to different consensus sequences on 





Figure 3-3. Consensus regions on U12-type and U2-type introns. 
(a) Sequence logos of nucleotides around 5’ splice site, 3’ splice site and the 
branch point in one form of U12-type introns, whose consensus region starts 
with GT and ends with AG.  
(b) The other form of U12-type intron whose consensus region starts with AT 
and ends with AC.  






To answer the question of how ZRSR2 mutation will affect splicing events in 
both U2-type and U12-type introns, we need to distinguish these two types of 
introns. Utilizing the difference in the consensuses (or motifs) of the 5’ splice 
site, 3’ splice site and the branch point between U2-type and U12-type introns 
(Patel and Steitz, 2003; Sheth et al., 2006; Tarn et al., 1995), we have developed 
a bioinformatics method for annotating introns into these two types. Figure 3-4 
indicates the workflow of our bioinformatics tool for annotating introns into U2 
and U12 types. The steps for intron U2-type or U12-type annotation can be 
explained as follows:  
1) By using UCSC hg19 Refseq GTF file, a total number of 211,123 different 
annotated introns are recorded. 
2) For each intron, sequences are extracted from 3nt upstream of the intron 
start site to the intron end site using the software Bedtools (Quinlan and 
Hall, 2010). 
3) Position Weight Matrix (PWM) of 5’ splice site in the two spliceosomes and 
BPS in U12 spliceosome are used for intron type classification.  
4) By using the 3nt upstream and 7nt downstream of the 5’ splice site, the 
starting 10nt sequences from the target intron are used for intron 
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classification in the first step. Two intron scores are calculated by using the 
PWM of 5’ splice site in U2 and U12 spliceosome as shown below.  






















Where 𝑃𝑖𝑁  is the value of nucleotide N at position i in the respective 
spliceosome PWM table (N=A/C/G/T, i=1…10).  
max (𝑃𝑖): The maximum value in PWM table at position i (i=1…10). 
min (𝑃𝑖): The minimum value in PWM table at position i (i=1…10). 
 
5) Utilizing the scores from the previous steps, introns are classified into two 
groups based on the following value: 
intron score = s(U12) − s(U2) 
s(U12): A score calculated with the U12 PWM from step 4. 
s(U2): A score calculated with the U2 PWM from step 4. 
For candidates with intron score >25, they are identified as U12-type 
introns. For candidates with intron score <10, they are identified as U2-type 
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introns. If the intron score is between 10 and 25, further analysis with the 
U12 PWM at BPS is required. 
6) Majority of the BPS of U2-type introns locate far away from the end of 
introns (>100nt) (Smith and Nadal-Ginard, 1989). However, the BPS of 
U12-type introns always locates at 8nt to 38nt upstream of the 3′ splice sites. 
Since BPS locates at different regions of different introns, BPS 
identification is performed on each position of the 8nt to 38nt upstream of 
the 3′ splice sites. And only introns with BPS score >65 are considered as 
U12-type introns.  
Score(U12 BPS) = 50 +











There are in total 732 U12-type introns discovered, which accounts for 0.3% of 
all introns in human genome. It has been found that the 732 U12-type introns 
are spliced by 1,445 annotated splice positions. 210,391 U2-type introns spliced 
by 395,593 annotated splice positions are also classified. Seven annotated splice 
sites could be spliced by either U12 spliceosome or U2 spliceosome depending 
on the introns. All the seven splice sites are annotated 5’ splice sites and are 
distinguished at the second step of intron classification. With different 3’ splice 
sites, some introns contain a BPS site at the required 8~38nt before the 3’ splice 
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sites and some do not. This results in the seven splice sites being spliced by U12 









3.3 Results and Discussion 
3.3.1 Increase in splicing events with ZRSR2 mutation 
In this study, SpliceScan used UCSC hg19 genome to find out the differential 
splicing candidates. After filtering sites with < 4 unannotated junction counts in 
all clinical samples, 298,275 positions in 15,737 genes are selected to detect the 
differential splicing.  
From Fisher’s exact test results, candidates with |∆SI| >20 and p<0.01 are 
reported as significant differential splicing events in SpliceScan. The numbers 
of differential splicing in group comparisons are depicted in Figure 3-5. Figure 
3-5a shows the 32 pairwise results of the numbers of globally unannotated 
splicing events in ZRSR2 MT versus ZRSR2 WT, while Figure 3-5b indicates 
that of ZRSR2 MT versus NC group comparison. The unannotated differential 
splicing in samples with ZRSR2 mutation is much higher than that of WT MDS 
or normal BM samples. This result indicates that unannotated splicing is more 





Figure 3-5. The numbers of globally unannotated splicing in group comparison 





3.3.2 Intron retention in MDS patients  
For all the annotated introns in the hg19 UCSC library, those with unannotated 
exon-intron junction reads bigger than 4 (A1+A2>4) in at least one clinical 
samples are identified as potential intron retention candidates. Based on this 
setting, SpliceScan selects 110,192 regions to further check the intron coverage 
and depth in all the clinical samples. 
The 110,192 regions are then classified to U2-type intron and U12-type intron. 
Figure 3-6 shows the U2-type and U12-type intron retention in group 
comparison of ZRSR2 MT versus ZRSR2 WT, ZRSR2 MT versus NC, and 
ZRSR2 WT versus NC. The dot plots are drawn based on the individual 
representatives while the density plot summarizes the changes in all the samples. 
As shown in the figure, U12-type introns retention always occurs with ZRSR2 
mutation in ZRSR2 MT versus ZRSR2 WT and ZRSR2 MT versus NC but 
without significant change in ZRSR2 WT versus NC, revealing U12-type 




(Madan et al., 2015) 
Figure 3-6. Differential intron retention in samples with ZRSR2 mutation. 
(a-c). Dot plots show intron retention in one representative pairwise analysis of 
ZRSR2 MT versus ZRSR2 WT (a), ZRSR2 MT versus NC (b) and ZRSR2 WT 
versus NC (c). Every dot represents an intron retention event and red dot refers 
to U12-type intron retention. (d-f). Distribution of U2-type and U12-type intron 
retention in all the 32 comparison of ZRSR2 MT versus ZRSR2 WT (d), ZRSR2 
MT versus NC (e), and 16 control comparisons of ZRSR2 WT versus NC (f). 
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Besides, SpliceScan analyzed intron retention in ZRSR2 MT versus ZRSR2 C 
group. By summarizing all the comparison results, every potential intron 
retention event in the ZRSR2 MT versus ZRSR2 C group comparison has two 
summary counts:  
1). In the 64 pairwise comparisons, the number of significant intron retention in 
ZRSR2 mutant samples (ΔSI >20, p<0.01).  
2). In the 64 pairwise comparison, the number of significant intron retention in 
control samples (ΔSI < -20, p<0.01). 
Exclusive of intron retention with mutant >0 and control >0, only candidates 
with stable change are selected to plot in Figure 3-7. If the number for defining 
the significant intron retention increases, the number of introns in both ZRSR2 
mutant and control drops quickly (Figure 3-7a). However, the component 
percentage of retained U12 intron in ZRSR2 mutant largely increases (Figure 
3-7b). In the ZRSR2 MT versus ZRSR2 C group comparison of intron retention, 
candidates with change number >41 are selected by requiring FDR<0.01. 
Specifically, 241 introns with mutant >41 and 0 intron with control >41 are 
finally discovered. In the 241 selected events, 85% of the introns are U12-type 
introns and 10.8% of introns come from U12-containing transcripts (Figure 3-
8). In human genome, U12-type intron only occurs for 0.3%, which is 
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significantly lower than the percentage in intron retention with ZRSR2 mutant.  
  
Figure 3-7. Comparison results of the significant groups.  
(a) The number of intron retention in ZRSR2 mutant and control with 
different comparisons requirement.  
(b) Intron retention competent of U2-type and U12-type in the ZRSR2 MT 




Figure 3-8. Composition of the intron retention candidates in samples with 
ZRSR2 mutation. 
(a) The introns retention with mutant > 41 in ZRSR2 MT versus ZRSR2 C 
group comparison. 









Apart from the pure bioinformatics analysis, experiment validations are applied 
to confirm the intron retention events. Figure 3-9 shows four representative 
U12-type intron retention events and intron retention in U12-containing 
transcript. As presented in the figure 3-9, the U12-type intron retention in both 
RNA-Seq and RT-PCR expression of genes are notable distinctive in ZRSR2 
mutant and control. Importantly, regions with U2-type intron retention almost 
all have an upstream U12-type intron retention. In general, both the splicing 
analysis and validation results confirm that intron retention are highly affected 










(Madan et al., 2015) 
Figure 3-9. Validation results for the representative U12-type intron retention 
candidates. 
Plots left are the normalized IGV expression plot and right are the RT-PCR 
expression results for the particular intron retention transcripts. 
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3.3.3 Other differential splicing events with ZRSR2 mutation  
Differential splicing changes not only happen on intron retention, but are also 
reported in the cases of alternative 5’ splice site and alternative 3’ splice site. 
Figure 3-10 shows a representative of alternative 5’ splice site in the U12-type 
intron, where the alternative 5’ splice site in FRA10AC1 gene forms a new 
unannotated U2-type intron. Experimental validation of RT-PCR and Sanger 
sequencing also confirms the analysis result of SpliceScan. By setting 
FDR<0.01 for 5’/3’ alternative splicing in SpliceScan, 53 unannotated introns 
are reported and out of which 42 events happen on U12-containing transcript. 
And all of the 42 events form unannotated U2-type introns to replace the 






(Madan et al., 2015) 
Figure 3-10. Alternative 5’ splice site in FRA10AC1. 
(a) RNA-Seq expression of FRA10AC1 gene in IGV.  
(b) The alternative 5’ site is marked as 4’ and the box bellowed the 4’ is the 
genome sequence around this site.  
(c) RT-PCR expression for some representative samples  
(d) Sanger result for the new forming transcript. The red line shows the 
connection point of the two exons. Sanger sequence and genome 






Similar analysis is done for exon skipping, and it is reported that 76% of exon 
skipping happens on U12-containing transcripts with > 31 exon skipping in 
mutant (FDR<0.01). It is found that almost all the U12-related events skip the 
U12-type introns and form a new U2-type intron in ZRSR2 mutant samples.  
The validation result of exon skipping and alternative splicing shows that 





Figure 3-11. Exon skipping in samples with ZRSR2 mutation. 
(a) U2 and U12 at the top refer to the original intron types and the bottom 
U2 is the new forming intron type.  
(b) The percentage of exon skipping in U12-containing transcripts and U2 









3.3.4 Isoform ratio changes on U12-containing genes 
The isoform ratio change of ZRSR2 MT versus ZRSR2 C shows high 
connections with U12 spliceosome. In MDS clinical dataset, 19 expressed genes 
are reported to have both the U12 isoforms and U2 isoforms. It is observed that 
the splicing ratio of U12-containing isoforms decreases while the splicing ratio 
of U2-containing isoforms increases for all the 19 genes in the samples with 
ZRSR2 mutations. The coherent results suggest that the differential splicing 
ratios are highly correlated to ZRSR2. In Figure 3-12, a representative of 




(Madan et al., 2015) 
Figure 3-12. Isoform ratio change in PFDN5. 
(a) Normalized RNA-Seq reads in PFDN5 gene shows with IGV.  
(b) Different intron types exist in U12-containing isoform and U2 isoform. 
U2 isoform refer to isoform only containing U2-type introns. 
(c) The splicing ratios of U12-containing isoform and U2 isoform in ZRSR2 
MT versus ZRSR2 C group comparison. 
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3.3.5 Enrichment analysis of differential splicing genes 
To further explore the regulating functions of ZRSR2 mutation in MDS 
development, an enrichment analysis with Gene Ontology (GO) is performed 
on DAVID website. The significant differential splicing candidates identified 
in ZRSR2 MT versus ZRSR2 C are the targets and the genes without significant 
splicing change are the background here.  
Figure 3-13 shows that the significant enrichment pathways (p<0.05) are ErbB 
signaling pathway, Chronic Myeloid Leukemia, MAPK signaling pathway, and 
Acute Myeloid Leukemia (Figure 3-13). In general, ZRSR2 mutation leads to 
splice change in U12-containing transcripts and these downstream targets have 





Figure 3-13. Gene Ontology (GO) enrichment with differential splicing genes. 
 
3.3.6 Differential splicing in ZRSR2 knockdown samples  
To further validate the function of ZRSR2, the ZRSR2 knockdown TF1 cell 
lines are analyzed by SpliceScan. The RNA-Seq of four knockdown samples 
are compared to their relevant controls and the events with p<0.01 are identified 
as our globally unannotated splicing candidates. As illustrated in Table 3-3, the 
numbers of unannotated splicing events in ZRSR2 knockdown samples 
(∆SI>5/10/15) are about 50% more than the controls (∆SI<-5/-10/-20) under 





Table 3-3. Numbers of globally unannotated splicing in shRNA vs scrambled 
sample control ∆SI>5 ∆SI<-5 ∆SI>10 ∆SI<-10 ∆SI>20 ∆SI<-20 
sh1_1 control_1 1510 1070 1011 685 447 309 
sh2_1 control_1 1400 846 851 539 372 221 
sh1_2 control_2 736 414 406 220 144 96 
sh2_2 control_2 599 376 366 211 158 98 
The splicing changes in ZRSR2 knockdown samples are consistent with that of 
ZRSR2 mutated MDS patients. However, the numbers of identified differential 
splicing candidates are significantly lower than those of the clinical ZRSR2 
mutated samples. To counter with this, a loose cutoff is used for defining the 
significant differential splicing candidates (|∆SI|>10, p<0.01). 
3.3.7 Intron retention in ZRSR2 knockdown samples 
The intron retention events are classified into two groups based on the intron 
type. The dot plots for ZRSR2 sh1 versus control sh1, ZRSR2 sh2 versus control 
sh2, and scrambled versus scrambled are drawn in Figure 3-14 as 
representatives. As shown in the figure, almost all the U12-type intron 
retentions occur in the ZRSR2 knockdown samples. And this suggests that 




Figure 3-14. The intron retention candidates in the ZRSR2 knockdown 
experiments.  
Red dots are U12-type introns and black dots are U2-type introns.  
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As shown in the overlapped area of the Venn diagram in Figure 3-15, there are 
some intron retention candidates identified both in ZRSR2 sh1 versus control 
sh and ZRSR2 sh2 versus control sh. The high composition of U12-type introns 
in this area reassures the results obtained from the samples with ZRSR2 
mutation, suggests that ZRSR2 plays an irreplaceable role in U12-type introns. 
 
Figure 3-15. The composition of intron retention in the two ZRSR2 knockdown 
experiments. 
(a) Overlap of intron retention in the two experiments.  




By analyzing the clinical samples with ZRSR2 mutation and ZRSR2 
knockdown cell line samples, the analysis results agree with each other and lead 
to a coherent conclusion--the comparatively large amount of unannotated 
splicing candidates implies that ZRSR2 plays an important role in the splicing 
process. Another observation is that differential splicing happens with all the 
patterns, and intron retention is the most affected pattern. 
ZRSR2 is reported as a key component in both the U2 and U12 spliceosomes, 
and the analysis results indicate that ZRSR2 plays different roles in the two 
spliceosomes. Furthermore, it is found that the majority of the differential 
splicing candidates show high correlation with U12 spliceosome. This suggests 
that ZRSR2 is a key protein for forming the U12 spliceosome assembly, but is 
a replaceable factor in U2 spliceosome assembly. GO enrichment analysis on 
the differential splicing candidates reveals that some pathways are related to 
leukemia, and this reassures the connections between ZRSR2 mutation and 
MDS.  
In conclusion, the analysis results show that ZRSR2 plays an indispensable role 
in U12 spliceosome assembly and thus affects the pathology of MDS. The direct 
regulating mechanism of ZRSR2 in MDS will be explored in future studies. 
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4 Chapter 4. Identification of splicing events under 
hypoxia conditions  
4.1 Introduction 
4.1.1 Background 
Hypoxia, a situation where a part of the body is short of oxygen supply, could 
lead to a number of adverse effects at the tissue level. Hypoxia is commonly 
observed in 50%-60% of human solid tumors. Protection against hypoxia in 
solid tumors is an important step in tumor development and progression (Cabral 
and Cerecetto, 2016; Gilkes et al., 2014; Spill et al., 2016).  
It became apparent that hypoxia can prevent cell death by provoking adaptive 
responses that, in turn, facilitate cell proliferation or angiogenesis, thus 
contributing to tumor progression. Under hypoxia, the adaptive responses of 
solid tumors may be initiated by expressing splicing variants via or 
independently of the hypoxia-inducible factor (HIF) pathway. To be adaptive in 
the long term, tumor cells should be able to survive hypoxia in the short term. 
Thus, to study tumor hypoxia responses, we need to consider the two hypoxia 
conditions: acute hypoxia and chronic hypoxia. It has been reported that the 
responses of hypoxia treatment under two hypoxia conditions are greatly 
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different from each other (Bayer and Vaupel, 2012). Under acute hypoxia 
environment, genomic instability hugely increases due to the decreasing 
effectiveness in the DNA damage repairing process, while a number of cellular 
processes are activated to increase the survival choices under chronic hypoxia 
environment (Pires et al., 2010). It was also reported that the activation of ionic 
sensitive channels for Ca2+, Na+, K+, and O2 can regulate gene expression by 
transcription factor HIFs under chronic hypoxia (Lopez-Barneo et al., 2001; 
Toescu, 2004). Another study showed that while the transcription factor HIF-1 
ubiquitously functions in all tissues, the transcription factor HIF-2 only 
functions in specific organs or tissues (Gordan and Simon, 2007). It waadapts 
discovered that HIF-1 regulates a number of biological processes under chronic 
hypoxia situation, which includes energy metabolism, 
cellular hypoxia adaptation, erythropoiesis, angiogenesis, differentiation, and 
proliferation (Fang et al., 2010; Song et al., 2015).  
4.1.2 Objectives 
 Identification of differential splicing under hypoxia conditions 
As mentioned above, solid tumors may express different splicing 
variants to adapt to hypoxia conditions, thus promoting survival and 
proliferation of tumor cell under hypoxia. The primary objective of this 
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study is therefore to identify differential splicing events (or genes) in 
tumor tissues in hypoxia environment. Here, the focus is on 
differentiating the splicing events in MCF7 cell lines under acute and 
chronic hypoxia treatments.  
 Splicing difference in acute and chronic hypoxia 
Since cellular responses are different with acute and chronic hypoxia 
treatments, it is of interest to explore how the splicing patterns differ 
from each other under the two hypoxia conditions. The objective is to 
identify the common as well as individual splicing events under the 
two conditions.  
 Exploring differentially spliced events for primary cancers 
In order to check whether the discovered differentially spliced 
candidates commonly exist in clinical samples, a number of cell lines 
would be treated with the same conditions in this study. The validation 
results would serve to distinguish if the differentially spliced genes are 
the common hypoxia regulating targets or are just tissue specific ones.  
 Prediction of potential motifs for regulating the differential 
splicing events 
One of the main objectives in this project is to identify the specific 
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motif regulating alternative splicing under the hypoxia environment. 
With the aid of bioinformatics computational tools, we want to predict 
potential regulating splicing factor from the RNA-Seq data of the 
MCF7 hypoxia samples. 
 Identification of regulating functions of these differentially spliced 
genes 
As the differentially spliced genes alter the biological processes and 
metabolism in cancer tissues, it is of interest to identify the enriched 
GO biological processes and molecular functions of these alternatively 
spliced genes.  
4.2 Methodology 
4.2.1 Samples 
In the following study, the MCF7 cell lines are treated with three different 
conditions: hypoxia 4h (acute hypoxia), hypoxia 24h (chronic hypoxia), and 
normoxia (serves as control). RNA-Seq data with 90bp paired-end length were 
obtained for the three samples. Mapping of RNA-Seq reads for all three samples 
was performed using the software STAR with human genome version hg19. 
The sequencing depth and mapping results are summarized in Table 4-1. The 
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high percentage of the uniquely mapped reads indicates that the samples 
prepared are of high quality and the analysis based on the RNA-Seq would be 
trustworthy. 
Table 4-1. Mapping summary of cell line samples 
 
Sample # of total reads # of uniquely 
mapped reads 
% of uniquely 
mapped reads 
Normoxia 174,512,164 162,759,662 93.27 
Acute hypoxia 
(Hypoxia 4h)  
176,070,129 165,128,413 93.79 
Chronic hypoxia 
(Hypoxia 24h) 
193,852,715 181,465,538 93.61 
4.2.2 Identification of differential splicing candidates 
Comparing the acute and chronic hypoxia samples to the normoxia sample, 
SpliceScan was applied to predict the differential splicing candidates. As the 
three samples are distinct and there is no biological replications in this study, 
Fisher’s exact test was employed to select significantly differential splicing 
events by the following two pairwise comparisons: acute hypoxia versus control 
(normoxia) and chronic hypoxia versus control. As adjusting of p value is 
recommended for multiple testing, the p values from fisher’s exact test were 
adjusted using the FDR approach. Finally, the following cutoff values were used 




4.2.3 Regulatory region selection 
It was reported that the functional region of the splicing regulatory elements is 
50-100nt around the splicing point for the four widely accepted simple splicing 
patterns (Fairbrother et al., 2004). For complex splicing pattern, however, the 
functional regulating region remains undiscovered and is therefore excluded 
from the motif analysis. The identified the differential splicing events are firstly 
classified into the four simple splicing patterns. This is then followed by 
checking the existence of a common motif in the regions around the splicing 
events, which could be the binding region for a regulatory splicing protein.  
It is known that different splicing patterns result in different binding regions for 
regulatory splicing proteins. The selection of binding regions should be 
therefore dependent on splicing patterns and is described as follows (Figure 4-
1).  
 Binding region for exon skipping events 
For the exon skipping (ES) candidates, the regulatory domain is either 
located at the skipped exon (SKE) region or at the two neighboring 
introns of the skipped exon. Thus, regions around the start and end 
positions of both the exon skipping events and the skipped exon(s) are 
selected as the potential regulatory domains and are marked by red 
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arrows in Figure 4-1. If more than one exon are skipped, only the first 
and the last ones of skipped exons are used. 
 Binding region for alternative 5’ splice site events 
Here, we include the alternative 5’ splice site events with annotated 
isoform ratio changes and the unannotated alternative 5’ splice events. 
The starting and ending sites of normal splicing, together with the 
alternative 5’ splice site are the target points in motif analysis and are 
marked by red arrows.  
 Binding region for alternative 3’ splice site events 
Similar to the definition of alternative 5’ splice site, the three points used 
for motif analysis include the starting and ending sites of normal splicing, 
and the alternative 3’ splice site. These significant differentially spliced 
events are either alternative 3’ splice site events with annotated isoform 
ratio changes or unannotated alternative 3’ splice events. 
 Binding region for intron retention events 
Intron retention happens when the normally spliced intron is not spliced. 
The target points are detected through comparing the intron retention 
transcript with the normal annotated transcript and are marked as red 
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arrows in Figure 4-1. 
 
  
Figure 4-1. The detected points of the four splicing patterns. 
SKE: skipped exon; ES: exon skipping; NS: normal splicing; A5: Alternative 5’ 
splice site; A3: Alternative 3’ splice site; IR: Intron retention.  
Red arrows indicate the detected points. Blue boxes represent the normal 
annotated transcripts from the annotation library. Orange boxes represent the 
differentially spliced candidates from SpliceScan output. The small blue arrows 
indicate the direction of the annotated transcripts.  
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4.2.4 Motif detection 
Putting all sequences within 100nt around the splice sites in all the splicing 
patterns together and dividing them into differentially up-spliced (ΔSI>10, p 
<0.01) sequences and down-spliced (ΔSI<-10, p <0.01) sequences, we applied 
the motif finding software called MEME-DREME (Bailey, 2011) to these two 
sets of sequences. When running the software tool, the up-spliced and down-
spliced sets of sequences were used as the input and background, respectively. 
In this way, we obtain the relatively enriched motifs in the up-spliced sequences. 
Vice versa we can obtain the relatively enriched motifs in the down-spliced 
sequences, when altering the two sequences for the input and background. The 
two sets of results for enriched motifs were then compared and analyzed to 
identify the potential motifs and thus the factors regulating alternative splicing 
in the hypoxia environment. Next, the enrichment of these motifs obtained from 
both sequence sets will be verified by using the human genome as the input in 
MEME-DREME. Only those motifs enriched in both runs of motif finding will 
be further considered. Using the enriched motifs, we can then scan the splicing 
events to determine their locations. Combining the information of the locations 
and splicing events, the type of the splicing regulatory element (ESE, ESS, ISE 
or ISS) can be determined, thus potential functions of the yet-to-be identified 
regulatory splicing factor(s) can be predicted. Finally, the enriched motifs were 
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compared to the factors with known motifs by using MEME-TOMTOM (Gupta 
et al., 2007) to give a hint about what factors could be.  
4.3 Results and Discussion 
4.3.1 Hypoxia regulates alternative splicing 
The samples treated with acute hypoxia and chronic hypoxia were analyzed 
using SpliceScan, respectively, and the differentially spliced candidates under 
the two hypoxia conditions are shown in Table 4-2. As shown in Table 4-2, 
there are more up-spliced events than down-spliced events in both unannotated 
splicing events and annotated isoform changing events. 
The unannotated splicing events are further classified according to the four basic 
splicing patterns: exon skipping, alternative 5’ splice site, alternative 3’ splice 
site, and intron retention. It can be seen that the up-spliced and down-spliced 
events are evenly distributed for the three splicing patterns: exon skipping, 
alternative 5’ splice site, alternative 3’ splice site, and isoform ratio change 
(Table 4-2). On the other hand, the number of up-spliced events is higher than 
the number of down-spliced events for the pattern of unannotated splicing in 
both acute hypoxia and chronic hypoxia. For intron retention, this number 
difference between up-spliced and down-spliced events becomes even inflamed 
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in both hypoxia conditions, indicating that under hypoxia MCF7 cells will 
undergo much more globally unannotated splicing and intron retention, thus the 
functions of the spliceosomes are impaired under hypoxia conditions. 
 
Table 4-2. Number of differential splicing candidates with acute and chronic 
hypoxia treatment in MCF7 cell lines. 
 
Splicing pattern 
# of acute hypoxia (hypoxia 
4h) (p<0.01)  
# of chronic hypoxia 
(hypoxia 24h) (p<0.01) 
ΔSI>10 ΔSI<-10 Total ΔSI>10 ΔSI<-10 Total 
Isoform ratio 
change 




1795 931 2726 1402 879 2281 
Exon skipping 367 385 752 318 402 720 
Alternative 5' 
splice site 
211 190 401 145 214 359 
Alternative 3' 
splice site 
201 222 423 164 238 402 






4.3.2 Splicing events validation 
In order to validate the differentially spliced candidates, experimental 
validations were carried out and the comparisons of experimental and 
computational results are presented in Table 4-3. In addition to RT-PCR, gel 
electrophoresis was also carried out. Along with experimental validation results, 
genome browser viewing was presented for two genes as examples. Figure 4-2 
shows exon skipping in LRCH3, and Figure 4.3 illustrates that an intron in 
LDHA is retained under hypoxia. Both splicing events become more significant 
as accurate hypoxia progresses to chronic hypoxia (Figures 4-2 & 4-3). All the 














LRCH3 25.78% 18.65% Exon skipping 
LDHA 61.40% 54.29% Intron retention 
PFKFB3 -27.03% -28.85% Isoform 
VGLL4 19.44% 32.52% Alternative 5’ splice site 
MARCH7 23.69% 13.58% Exon skipping 
FUT11 47.48% 38.73% Complex 
NFE2L1 15.77% 10.50% Alternative 5’ splice site 
MXI1 -30.44% -51.19% Alternative 5’ splice site 
AHNAK 68.05% 68.10% Alternative 5’ splice site 
TNFSF13 44.55% 30.25% Intron retention 
ARHGAP4 33.48% 20.44% Intron retention 




Figure 4-2. Exon skipping validation results in LRCH3 gene. 
(a) The raw junction counts are presented in sashimi plots using the 
software IGV. The annotated transcript in hg19 is colored in blue and 
drawn on the top. 
(b) This is the gel electrophoresis results for the LRCH3 gene.  
(c) The ratio of the transcript containing exon skipping in LRCH3 is shown 
in the barplot above. The bar marked by “*” indicates that the ratio is 
significantly higher in the hypoxia 24h sample while compared to the 





Figure 4-3. Validation results of intron retention in LDHA gene. 
(a) The raw junctions counts are presented in sashimi plots using the 
software IGV. The annotated transcript in hg19 is colored in blue and 
drawn on the top. 
(b) This is the gel electrophoresis results for the LDHA gene.  
(c) The ratio of the transcript containing intron retention in LDHA is shown 
in the barplot above. The bar marked by “**” indicates that the ratio is 
significantly higher in the hypoxia samples while compared to the 










4.3.3 Common differential splicing event in other cell lines 
In the following study, we want to explore if the splicing events found in MCF7 
cell lines under hypoxia treatment are tissues specific or commonly found in 
other hypoxia treated samples. To achieve this, the differential splicing 
candidates found in the MCF7 cell lines (Table 4-3) are assessed in other cell 
lines with the same hypoxia treatments. To be specific, MDA-MB-231(breast 
cancer), HELA (human cervical cancer), and SKNBE (2) C (human 
neuroblastoma) cell lines are treated with acute hypoxia 4h and chronic hypoxia 
24h, respectively.  
Comparing the experimental results from other cell lines with MCF7 cell line, 
it has been found that there are no significant splicing alternations for TNFSF13, 
ARHGAP4, MARCH7, AHNAK, and LRCH3 between normoxia and hypoxia 
for other three tested cell lines. The rest of the splicing candidates (Table 4-3) 
are commonly found in all the four cell lines and are believed to be the 
regulating differential splicing candidates in the hypoxia environment. NFE2L1 
and PCBP2 are selected as representatives and the detailed validation results are 
shown in Figure 4-4 for NFE2L1 and Figure 4-5 for PCBP2, respectively. 
Within the last intron of NFE2L1, there is a novel transcript with an exon linking 
to the last NFE2L1 exon. Expression intensity of this novel transcript increases 
120 
 
from normoxia to accurate hypoxia to chronic hypoxia, while the expression 
intensity of the known transcript remains almost the same for all three 
conditions. Assuming that the new transcript was an NFE2L1 isoform, the 
isoform ratio change increases as hypoxia progresses (Fig 4-4). The total counts 
or expression intensity of PCBP2 remains almost at the level for all three 
conditions. However, the number of the junction reads increases significantly at 
chronic hypoxia, compared to normoxia and acute hypoxia. This exon skipping 




Figure 4-4. The commonly found differential splicing event in NFE2L1. 
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(a) The raw junction counts for NFE2L1 gene are presented in sashimi plots 
using the software IGV. The annotated transcript in hg19 is colored in 
blue and drawn on the top. The alternative 5’ splicing happens at the 
first exon and is marked as AFE (alternative splicing at first exon) in the 
following plots. 
(b) The RT-PCR results for the expression of the two transcripts in NFE2L1 
gene in MCF7 cell lines are plotted in a bar plot on the left. The ratio of 
the transcripts containing the alternative 5’ splice site in NFE2L1 is 
plotted in a bar plot on the right.  
(c) Same plots are drawn for the MDA-MB-231 cell line.  
(d) Same plots are drawn for the HELA cell line. 
(e) Same plots are drawn for the SKNBE (2) C cell line. 
 
“*” indicates that the expression level or ratio significantly increases in 
comparison with the normoxia sample at p≤ 0.05. 
“**” indicates that the expression level or ratio significantly increases 









Figure 4-5. The commonly found differential splicing event in PCBP2. 
(a) The raw junction counts for PCBP2 gene are presented in sashimi plots 
using the software IGV. The annotated transcript in hg19 is colored in 
blue and drawn on the top. 
(b) The RT-PCR results for the expression of the two transcripts in PCBP2 
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gene in MCF7 cell line is plotted in a bar plot.  
(c) The ratio of the transcripts containing the exon skipping events in 
PCBP2 in MCF7 cell line is plotted in a bar plot.  
(d) The RT-PCR results for the expression of the two transcripts in PCBP2 
gene in MDA-MB-231 cell line is plotted in a bar plot.  
(e) The ratio of the transcripts containing the exon skipping events in 
PCBP2 in MDA-MB-231 cell line is plotted in a bar plot.  
 
“*” indicates that the expression level or ratio significantly increases in 
comparison with the normoxia sample at p≤ 0.05. 
“**” indicates that the expression level or ratio significantly increases 
in comparison with the normoxia sample at p≤ 0.01. 
 
 
4.3.4 Prediction of regulatory motifs of splicing factors and 
potential splicing factors regulating splicing in hypoxia 
As mentioned above, the sequences at splice sites of all identified spliced genes 
were pulled together and submitted to motif finding using MEME-DREME 
using only up-spliced events versus down-spliced events. The analysis yields 
only an enriched motif GGWC (where W=A/T) (Figure 4-6).  
 
 
Figure 4-6. Identified motif based on the sequences at splice sites which may 
regulate exon skipping in chronic hypoxia. 
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This motif GGWC was further filtered for potential sites by comparing 
differential splicing events versus genome background. Figure 4-7 shows that 
in all potential splice sites, enrichment for this motif was for splice sites of 
skipped regions/exons with significant enrichment fold changes between 
negative ΔSI splice sites and positive ΔSI splice sites. This enrichment is only 
found in the chronic hypoxia condition (Figure 4-7b), but not in the acute 
hypoxia condition (Figure 4-7c), indicating that chronic hypoxia may recruit an 




Figure 4-7. The relative enrichment of GGWC motif in the exon skipping 
regions.  
(a) Exon skipping event where the red boxes are the skipped exon regions. 
(b) The relative enrichment of GGWC motif in the exon skipping regions 
under chronic hypoxia.  
(c) The relative enrichment of GGWC motif in the exon skipping regions 
under acute hypoxia.  
The red dashed boxes indicate the skipped exon regions where motif enrichment 
analysis is carried out. “***” indicates that the difference with significant 








Comparing the splicing motif (GGWC) with the publically available DNA-
protein binding databases (Paz et al., 2014), SRSF7 with the motif 
WGGACRA(W=A/T, R=A/G) is a potential candidate. SRSF7 is a SR 
activating factor, which promotes the intron removal process. However, no 
differential splicing was detected in SRSF7 in both the acute hypoxia sample 
and chronic hypoxia sample compared to normoxia. Furthermore, based on the 
RNA-Seq expression analysis result, no significant expression change was 
observed in the MCF7 cell line under the chronic/acute hypoxia settings as 
shown in Figure 4-8. The above observations suggest that SRSF7 may not be 
the splicing regulating factor under hypoxia environment. On the other hand, 
besides SRSF7, no other splicing factors can be found for the GGTC motif in 
the public splicing factor databases.  
Additional comparing analysis of the GGWC motif with the public RNA 
binding protein database was carried out in MEME-TOMATO. Three RNA-
binding proteins were identified to have similar motif to GGWC (Figure 4-9). 
Nevertheless, it was found that all of the three reported motifs all bind on RNAs 
on the reverse strand, which is contrary to the binding direction in the splicing 
event sequences. Moreover, the similarity between the GGWC motif and the 
three reported motifs is quite low, as shown in Figure 4-9. The enrichment of 
the reported motifs in the chronic hypoxia exon-skipping regions was also 
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analyzed. The analysis results show that there is no significant enrichment for 
any of the three motifs in these exon-skipping regions. Thus, the functional 
GGWC motif is very likely to be bound with a new splicing factor which 
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4.3.5 GO functional analysis of spliced genes in hypoxia 
After identifying the alternative splicing candidates in acute hypoxia and 
chronic hypoxia conditions, the differentially spliced genes with annotated 
isoform changes and unannotated splicing cases are compared. Figure 4-10 
shows the individual numbers of differentially spliced genes in both acute and 
chronic hypoxia compared to normoxia. As shown in Figure 4-10, there are a 
number of common differentially spliced genes between the two hypoxia 
conditions while there are also a good of differentially spliced genes specific to 
each hypoxia condition. Thus, we divided all differentially spliced genes into 
three groups: 1) common differentially spliced genes between the two hypoxia 
conditions; 2) differentially spliced genes specific to acute hypoxia; and 3) 
differentially spliced genes specific to chronic hypoxia. GO enrichment analysis 
was performed for each of these three groups of splicing genes using the 
software Enricher (Chen et al., 2013).  
From the GO analysis results, the top ten enriched biological processes and 
molecular functions for each group of differentially spliced genes are listed in 
Tables 4-4 and 4-5. The enrichment score, which is the product of –log10 (p) 
and Z score, is used as an estimator for the enrichment level. The enrichment 
scores cross the three groups of differentially spliced genes are illustrated in 
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Figure 4-11 for a better understanding of what is enriched for which hypoxia 
condition.  
In the acute differentially spliced genes, DNA repairing is identified to as the 
top biological process. It is known that DNA repairing plays a vital role in tumor 
development and is highly regulated by hypoxia. Some of the highly enriched 
biological processes appear in the acute differentially spliced genes as well as 
in the common group of differentially spliced genes. The rest of the enriched 
biological processes are related to neurons or guanyl-nucleotide exchange 
factors, which were reported to be highly correlated with hypoxia processes 
(Irani and Goldschmidt-Clermont, 1998; Oosthuyse et al., 2001).  
In the chronic differentially spliced genes, the protein serine/threonine kinase 
activity is the top listed among all GO molecular function terms. The protein 
serine/threonine kinase activity is well known for inhibiting the HIF-1 
expression (Wang et al., 1995). ATP binding is identified to be the one with the 
2nd highest enrichment score. The high enrichment level for ATP binding is 
reasonable in the sense that hypoxia results in insufficient ATP supply.  
ATP binding is listed at the 2nd top. The high enrichment level for ATP binding 
is reasonable in the sense that hypoxia will lead to insufficient ATP supply.  
In the common differentially spliced genes, GO analysis show the following 
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term are enriched: GTP regulation, Ras GTPase, DNA repairing, and guanyl-
nucleotide exchange factor activity. All of these terms are somehow related to 
hypoxia.  
The functional enrichment analysis proves that the differential splicing 
candidates play very important roles in response to hypoxia signals. It also 






Figure 4-10. Venn diagram showing the splicing genes between acute hypoxia 
and chronic hypoxia compared to normoxia. 
Venn diagram showing the common and specific numbers of a) genes with 
isoform ratio change, b) genes of unannotated splicing and c) differential 






Figure 4-11. Enriched GO biological processes (A) and molecular functions (B) 




Table 4-4. Enrichment scores for the top 10 enriched GO biological processes 
in hypoxia conditions 












positive regulation of GTPase 
activity 
15.07 4.4  
2 
positive regulation of GTP 
catabolic process 
15.07 4.4  
3 regulation of Ras GTPase activity 7.24 7.49  
4 DNA repair 4.36 14.31 3.08 
5 chromatin modification 4.25   
6 
regulation of small GTPase 
mediated signal transduction 
4.15   
7 cilium assembly 3.98   
8 histone modification 3.98   
9 
positive regulation of Ras GTPase 
activity 
3.94 3.43  
10 covalent chromatin modification 3.83   
11 
regulation of gene expression, 
epigenetic 
 7.49  
12 mannosylation  3.74  
13 regulation of axonogenesis  3.66  
14 methylation  3.21  
15 
negative regulation of neuron 
projection development 
 3.2  
16 nuclear division   7.86 
17 mitotic nuclear division   7.74 
18 protein autophosphorylation   7.74 
19 organelle fission   5.04 
20 organelle assembly   4.52 
21 DNA replication   4.2 
22 cell projection assembly   2.88 




  2.08 
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Table 4-5. Enrichment scores for the top 10 enriched GO molecular functions 
in hypoxia conditions 











1 GTPase regulator activity 9.7   
2 guanyl-nucleotide exchange factor activity 9.57 7.28  
3 nucleoside-triphosphatase regulator activity 9.3   
4 GTPase activator activity 9.17   
5 ATP binding 8.85  14.47 
6 enzyme activator activity 6.36   
7 small GTPase regulator activity 5.16   
8 ARF guanyl-nucleotide exchange factor 
activity 
4.65   
9 Ras guanyl-nucleotide exchange factor 
activity 
4.4 6.86  
10 chromatin binding 3.71   
11 methylated histone binding  6.58  
12 mannosyltransferase activity  6.24  
13 Rab guanyl-nucleotide exchange factor 
activity 
 5.79  
14 tubulin binding  4.92  
15 O-methyltransferase activity  4.43  
16 S-adenosylmethionine-dependent 
methyltransferase activity 
 4.12  
17 hydrolase activity, acting on glycosyl bonds  4.07  
18 protein serine/threonine kinase activity   15.18 
19 zinc ion binding   2.22 
20 glutamate receptor binding   1.69 
21 RNA polymerase II transcription corepressor 
activity 
  1.66 
22 protein kinase binding   1.55 
23 DNA-directed DNA polymerase activity   1.54 
24 RNA polymerase II transcription factor 
binding transcription factor activity involved 
in negative regulation of transcription 
  1.5 
25 kinase binding   1.5 
26 transcription factor binding   1.49 
4.4 Conclusion 
The unbalanced number of up-regulated and down-regulated differential 
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splicing events from SpliceScan output demonstrates that hypoxia leads to 
increasing differential splicing in hypoxia condition. With more affected events 
in acute hypoxia than in chronic hypoxia, intron retention is the most affected 
pattern in acute hypoxia. This is useful in the sense that intron retention is the 
easiest detectable feature for all cancers, and an increase in number could give 
us some information about cancer development (Dvinge and Bradley, 2015). 
Furthermore, the motif GGWC is discovered to regulate differential exon 
skipping events in the chronic hypoxia candidates. It is noticed that regions with 
less GGWC motif have higher possibility to be skipped during the splicing 
process in MCF7 cell line under chronic hypoxia. This results in shorter 
transcripts being generated, and sometimes leads to a loss of function in proteins.  
From the results of GO enrichment analysis for biological process and 
molecular function, it is found that the enriched GO terms are highly related to 
some published hypoxia regulating pathways. And the functional analysis also 
proves that the identified splicing candidates from SpliceScan are reliable and 
meaningful. 
In MCF7 cell line, the motif GGWC shows less enrichment in the skipped 
region under chronic hypoxia situation. And significant change in enrichment 
of GGWC motif is observed both at the start of SKE in the 50-100nt 
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downstream and at the end of SKE in the 50-100nt upstream. GGWC motif is 
therefore believed to be a cis-acting regulatory element which regulates splicing 
in the chronic hypoxia environment. However, further study is needed in order 
to identify the exact binding protein. In the future, analysis on other chronic 
hypoxia samples should be carried out to assess if GGWC is a common motif 
under hypoxia environment or is just tissue specific.  
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5 Chapter 5. Overall conclusion 
Utilizing the developed software tool SpliceScan, the first project examined the 
unannotated splicing caused by ZRSR2 defects in MDS samples. In this project, 
intron retention is identified to be the most common unannotated splicing 
pattern caused by ZRSR2 defects and more than 90% of the found events are 
related to U12-type introns. These findings demonstrate that in MDS patients, 
ZRSR2 defects lead to alternative patterns of unannotated splicing and ZRSR2 
plays an indispensable role in the splicing of U12-type intron. The regulating 
functions of ZRSR2 in MDS is important as understanding the connections 
between spliceosome mutation and tumorigensis is helpful in developing 
possible cures of diseases. However, the detailed mechanism of ZRSR2 in 
clinical MDS remains undercover as the RNA samples are insufficient to do 
further molecular analysis. To address this problem, protein analysis of ZRSR2 
knockdown in cell lines will be carried out in the future. 
In the second project, splicing difference caused by hypoxia is investigated in 
MCF7 cell lines under three conditions: the normoxia condition, the 4h acute 
hypoxia condition, and the 24h chronic hypoxia condition. SpliceScan results 
show that more unannotated alternative splicing cases are found in hypoxia 
samples. Different from other preliminary studies analyzing the expression of 
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genes in breast cancer, this project analyzed genome-wide splicing changes in 
hypoxia MCF7 cell line, and confirms the perspective--differential splicing in 
hypoxia possibly leads to high-risk in cancer development (Favaro et al., 2011). 
Another important finding of this project is the identification of the noval motif 
GGWC, which regulates exon skipping events in chronic hypoxia. In the next 
step, we aim to identify the exact functional splicing factor that encode GGWC. 
Further analysis on other chronic hypoxia samples would also be carried out in 
the future.  
From the two projects mentioned above, we can see that SpliceScan 
successfully identifies the alternative splicing events with unannotated splicing 
changes. Moreover, SpliceScan not only detects the differentially spliced events 
in simple forms like exon skipping, intron retention, mutually exclusive exon, 
alternative 5’ splice site, and alternative 3’ splice site, but is also capable of 
detecting splicing events in complex forms. As complex splicing is observed in 
more than 30% of alternative splicing events in human and the percentage goes 
even higher in tumors, we would say that SpliceScan is a suitable choice for 
splicing analysis in cancer samples. 
Aside from accurately identifying the differential splicing candidates, 
SpliceScan is very user friendly as it requires minimal computing power in 
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terms of CPU time and threads required. The highly accurate splicing 
identification achieved by SpliceScan would also be useful in exploring possible 
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